ID stringlengths 13 17 | question stringlengths 88 1.13k | answer stringlengths 6 156 | reference_sequence stringlengths 4.1k 4.1k | variant_sequence stringlengths 4.1k 4.1k |
|---|---|---|---|---|
Task1_train_3100 | This alteration occurs within gene PXDN (peroxidasin) located on Chromosome 2. Is it associated with a disease or is it a benign variant? | Pathogenic; Anterior segment dysgenesis 7 | CTTTGCCATTTTTTCCACCCCACAGGGTCCGAGGTCTCCTAATCTACCTGGCCAGCTTCCCTTGTCTCAGGGGTGACAGCGTCCCATTTTGCCTTTGTGGCAGAACAAGGAGAACCGCACCCACAGGTGATCAAGGCTGTGGCTCAGAAGCGGCGCCATCTGTGGCGGTCATGGGCAGGTGGCCCCACAGGCCTGGGTCTGGGCAACACAGTGAGTATGGAAGATGCTACAGGCCAAGCCTTAGGGGCTGGTGGCCCCAAGGGCCCGGATCTGCAGACACCAAGCTCTGCCTCTCTCTCTGCCCCTGATACAACAGCAGG... | CTTTGCCATTTTTTCCACCCCACAGGGTCCGAGGTCTCCTAATCTACCTGGCCAGCTTCCCTTGTCTCAGGGGTGACAGCGTCCCATTTTGCCTTTGTGGCAGAACAAGGAGAACCGCACCCACAGGTGATCAAGGCTGTGGCTCAGAAGCGGCGCCATCTGTGGCGGTCATGGGCAGGTGGCCCCACAGGCCTGGGTCTGGGCAACACAGTGAGTATGGAAGATGCTACAGGCCAAGCCTTAGGGGCTGGTGGCCCCAAGGGCCCGGATCTGCAGACACCAAGCTCTGCCTCTCTCTCTGCCCCTGATACAACAGCAGG... |
Task1_train_3101 | This gene mutation involves PXDN (peroxidasin) on Chromosome 2. Is it associated with any clinical condition, or is it benign? | Pathogenic; Anterior segment dysgenesis 7 | TGTTGTGCGAGTGGACGATGATGTCACCCGTCTACTCTCAGCTCCTTTTTCAAATTCGGTGAGGCGTTTGTGGACGAGCACACCATGCAAAGCGGAGCAGAGGACCCCATGTGTGTCCTACGACACTTATTTTAACATGTTATTTTCAACAAGCAATTAATATTCCGGGGCAAAACATACCGCAAGCTTTATGAAACTGACCAGATGGGAAAAATCTTTGAGGTGCCATTTTTCCACTGGCTCAGCAAGAATTACATTATCCAGACCCAGGGAAACCTCACCCGGCTCCATTCTAAAAGTCCACTGCTGTTGAGTGAGAT... | TGTTGTGCGAGTGGACGATGATGTCACCCGTCTACTCTCAGCTCCTTTTTCAAATTCGGTGAGGCGTTTGTGGACGAGCACACCATGCAAAGCGGAGCAGAGGACCCCATGTGTGTCCTACGACACTTATTTTAACATGTTATTTTCAACAAGCAATTAATATTCCGGGGCAAAACATACCGCAAGCTTTATGAAACTGACCAGATGGGAAAAATCTTTGAGGTGCCATTTTTCCACTGGCTCAGCAAGAATTACATTATCCAGACCCAGGGAAACCTCACCCGGCTCCATTCTAAAAGTCCACTGCTGTTGAGTGAGAT... |
Task1_train_3102 | A sequence alteration has been identified in MYT1L (myelin transcription factor 1 like) on Chromosome 2. Is it disease-inducing or harmless? | Pathogenic; Intellectual disability | ACCATGAAGCAACATTTGGTCATTGAAACATTAGTGTTTTTATAGAAGATGCTTGATTGAAATTCTTAGTTTTGAAGATCCATTCATAGAAAGGGACAATTTAAGAAATTCAGTCAAGTTCAGATTTCCCAGAAAGGCTCTATCAGAATAGGATTGACTTTTTGCAAAGATAGGTTTAGACACATGTGTGGCTTTTCGATCAACCAAAATTAGCAAAAGGCCATCCACCTCCTGTAAGATACAGTCTCCCCTCCAGGACAAGACAGGAAGGAGGGGCTGCCCATGCGCACCCTGCCCTGGAAGGCATGAAGAGCTAACCG... | ACCATGAAGCAACATTTGGTCATTGAAACATTAGTGTTTTTATAGAAGATGCTTGATTGAAATTCTTAGTTTTGAAGATCCATTCATAGAAAGGGACAATTTAAGAAATTCAGTCAAGTTCAGATTTCCCAGAAAGGCTCTATCAGAATAGGATTGACTTTTTGCAAAGATAGGTTTAGACACATGTGTGGCTTTTCGATCAACCAAAATTAGCAAAAGGCCATCCACCTCCTGTAAGATACAGTCTCCCCTCCAGGACAAGACAGGAAGGAGGGGCTGCCCATGCGCACCCTGCCCTGGAAGGCATGAAGAGCTAACCG... |
Task1_train_3103 | Here’s a variant in MYT1L (myelin transcription factor 1 like) located on Chromosome 2. What is the predicted biological effect — harmless or disease-causing? | Pathogenic; Intellectual disability, autosomal dominant 39 | CCAATTCTCTCATGTAAATTGTCACAGCGAATCCGCAGACACCAGGGGAAGAATGACACCCTTGCCCTCACACAGCCTGGCCTGGAGTGAGGGGTCCTGGCCCCGGCTTCCAGCACAGCCCCGCCCTCCAGTCCCTGCCCCTGCTGCTGTAGGGACATGCCCTGAGCGGGTGTCCCCAGCGCTCCGAGGTGTGGGGCAGACTATGGATAGAGCTCACGGATGGTGCACTCCTGCTGGGTACCTGAGCACGCGGTCCGAGGCCTGGCTGGACTTGGACACGTCGCAGCTCTGGTGCTTTTCCTGTGCCTTGGCCAGTTTCT... | CCAATTCTCTCATGTAAATTGTCACAGCGAATCCGCAGACACCAGGGGAAGAATGACACCCTTGCCCTCACACAGCCTGGCCTGGAGTGAGGGGTCCTGGCCCCGGCTTCCAGCACAGCCCCGCCCTCCAGTCCCTGCCCCTGCTGCTGTAGGGACATGCCCTGAGCGGGTGTCCCCAGCGCTCCGAGGTGTGGGGCAGACTATGGATAGAGCTCACGGATGGTGCACTCCTGCTGGGTACCTGAGCACGCGGTCCGAGGCCTGGCTGGACTTGGACACGTCGCAGCTCTGGTGCTTTTCCTGTGCCTTGGCCAGTTTCT... |
Task1_train_3104 | This variant affects the gene MYT1L (myelin transcription factor 1 like) found on Chromosome 2. What is the clinical effect of this variant — benign or pathogenic? State the disease if applicable. | Pathogenic; Intellectual disability, autosomal dominant 39 | AGGGGAAACTAGCCCAGAAAAAAAAAATTAAAAGCCTTCTATGGATGGAATTCTCTAATTGTTTTAGTAAATGCTTGTGGTGTTATAAAGAATCGCACAGGAGCAAAGGCTGAGAAGCCTCCTCTGTATTGTCTGGCATGCACCTGTGCCGCCCATGTCAGAGCTGACTCTCCTTGCCTCCGAGAGCGATCTGGCCCTGGGAGGCACCTGCAGCCGGCGCGAAGGGCACCTTGCCAGTCCCACTCCACAGTCCCACTTCATTTAGGCCTGTCCTGTGAAAACAGGGAGTCAGAAGAATTTCCCATCCATAAAAAGGAGCT... | AGGGGAAACTAGCCCAGAAAAAAAAAATTAAAAGCCTTCTATGGATGGAATTCTCTAATTGTTTTAGTAAATGCTTGTGGTGTTATAAAGAATCGCACAGGAGCAAAGGCTGAGAAGCCTCCTCTGTATTGTCTGGCATGCACCTGTGCCGCCCATGTCAGAGCTGACTCTCCTTGCCTCCGAGAGCGATCTGGCCCTGGGAGGCACCTGCAGCCGGCGCGAAGGGCACCTTGCCAGTCCCACTCCACAGTCCCACTTCATTTAGGCCTGTCCTGTGAAAACAGGGAGTCAGAAGAATTTCCCATCCATAAAAAGGAGCT... |
Task1_train_3105 | With a mutation on Chromosome 2 in gene RNASEH1 (ribonuclease H1), classify this variant as benign or pathogenic. Include the disease if it's pathogenic. | Pathogenic; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2 | GGCTGAGGCACGAGAATCACTTGAACCCAGAAGGCAGAGGTTGCAATGAGATCACGCCATAGCCTGGGGTGACAGAGTGAGACCTGTCTCAAAAACCAAACCAAAAAACTGTATTACTTGTATGATAAGGAAAATAATCAAATTTGTGTATGTGGGTGGGTTTGTTTTGTTTTTCTGAGACAGGGTCTCACTCTGTCGCCCAGGCTAGAGTACAGTGGTACAATCTTGGCTCACTGCAACCTCGACCTCCCCAGCTCAAGTCATCCTCCCACCTCAGTGTCCTGAGTAACTAGACTACAGGCATGTGCCACTACCCCTGG... | GGCTGAGGCACGAGAATCACTTGAACCCAGAAGGCAGAGGTTGCAATGAGATCACGCCATAGCCTGGGGTGACAGAGTGAGACCTGTCTCAAAAACCAAACCAAAAAACTGTATTACTTGTATGATAAGGAAAATAATCAAATTTGTGTATGTGGGTGGGTTTGTTTTGTTTTTCTGAGACAGGGTCTCACTCTGTCGCCCAGGCTAGAGTACAGTGGTACAATCTTGGCTCACTGCAACCTCGACCTCCCCAGCTCAAGTCATCCTCCCACCTCAGTGTCCTGAGTAACTAGACTACAGGCATGTGCCACTACCCCTGG... |
Task1_train_3106 | The gene COLEC11 (collectin subfamily member 11) on Chromosome 2 carries this variant. Does this mutation lead to a specific disease, or is it non-pathogenic? | Pathogenic; 3MC syndrome 2 | GGCTCTACGTGATTGCCGACGTCCAGAAAGAGGGATTGAACTTCTACAGGATATGCCAGACTGCAGGGTGGGCTGAGACTCTGCCCAGTGGAAACTGTGGGAAAAGGCGTAAAGCCCACCCGCACACCGCAGCGATGGGGGTGGATGGTGAGGTGCTGGGCAGGCCCAGGCTCCGATCCTGGGGACAGGCAGAGGCTGCTGGGCCACGGGGAGCCCCGGCACCACGGAGGCGATGACCAGGTGTCACTCTTCACAGGAAGAAGGTTAGGGTCCGTCCAGGGACTAGGAACAAACTCGCAGCCGGAGGGAATCGGTTGGCA... | GGCTCTACGTGATTGCCGACGTCCAGAAAGAGGGATTGAACTTCTACAGGATATGCCAGACTGCAGGGTGGGCTGAGACTCTGCCCAGTGGAAACTGTGGGAAAAGGCGTAAAGCCCACCCGCACACCGCAGCGATGGGGGTGGATGGTGAGGTGCTGGGCAGGCCCAGGCTCCGATCCTGGGGACAGGCAGAGGCTGCTGGGCCACGGGGAGCCCCGGCACCACGGAGGCGATGACCAGGTGTCACTCTTCACAGGAAGAAGGTTAGGGTCCGTCCAGGGACTAGGAACAAACTCGCAGCCGGAGGGAATCGGTTGGCA... |
Task1_train_3107 | A variant was discovered on Chromosome 2, affecting COLEC11 (collectin subfamily member 11). What is its functional impact — neutral or pathogenic? State the disease if pathogenic. | Pathogenic; not provided | GGCGTAAAGCCCACCCGCACACCGCAGCGATGGGGGTGGATGGTGAGGTGCTGGGCAGGCCCAGGCTCCGATCCTGGGGACAGGCAGAGGCTGCTGGGCCACGGGGAGCCCCGGCACCACGGAGGCGATGACCAGGTGTCACTCTTCACAGGAAGAAGGTTAGGGTCCGTCCAGGGACTAGGAACAAACTCGCAGCCGGAGGGAATCGGTTGGCAGAACTGGGAGGGCGGAGTGTAGCTCAGTTGATTAGCGAGAGAAGACTTAGGACAGCTGCGTGTTCTGGACACCGTGCCGTCTGCGAGGCATCAGAGGGACTTCCC... | GGCGTAAAGCCCACCCGCACACCGCAGCGATGGGGGTGGATGGTGAGGTGCTGGGCAGGCCCAGGCTCCGATCCTGGGGACAGGCAGAGGCTGCTGGGCCACGGGGAGCCCCGGCACCACGGAGGCGATGACCAGGTGTCACTCTTCACAGGAAGAAGGTTAGGGTCCGTCCAGGGACTAGGAACAAACTCGCAGCCGGAGGGAATCGGTTGGCAGAACTGGGAGGGCGGAGTGTAGCTCAGTTGATTAGCGAGAGAAGACTTAGGACAGCTGCGTGTTCTGGACACCGTGCCGTCTGCGAGGCATCAGAGGGACTTCCC... |
Task1_train_3108 | The gene SOX11 (SRY-box transcription factor 11), on Chromosome 2, contains a mutation. Does this mutation cause a disorder, or is it a benign change? | Pathogenic; Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism | ACCTGAAAGGAAGCAGATTCGGATAATTTTCCCAGTCCTACACGGCTGATTTCTCTGGTGAAGGGATCCGGGCAGTGTCTTAGGAACTGCTCAAAGTTCCCAGATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCAC... | ACCTGAAAGGAAGCAGATTCGGATAATTTTCCCAGTCCTACACGGCTGATTTCTCTGGTGAAGGGATCCGGGCAGTGTCTTAGGAACTGCTCAAAGTTCCCAGATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCAC... |
Task1_train_3109 | A genetic alteration is present in SOX11 (SRY-box transcription factor 11) on Chromosome 2. Is this variant benign or disease-causing, and if the latter, which condition is involved? | Pathogenic; Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism | CTGAAAGGAAGCAGATTCGGATAATTTTCCCAGTCCTACACGGCTGATTTCTCTGGTGAAGGGATCCGGGCAGTGTCTTAGGAACTGCTCAAAGTTCCCAGATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCT... | CTGAAAGGAAGCAGATTCGGATAATTTTCCCAGTCCTACACGGCTGATTTCTCTGGTGAAGGGATCCGGGCAGTGTCTTAGGAACTGCTCAAAGTTCCCAGATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCT... |
Task1_train_3110 | A variant was discovered in gene SOX11 (SRY-box transcription factor 11), Chromosome 2. Please indicate if this mutation results in a known disease or if it's non-harmful. | Pathogenic; Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism | CCCAGTCCTACACGGCTGATTTCTCTGGTGAAGGGATCCGGGCAGTGTCTTAGGAACTGCTCAAAGTTCCCAGATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCTTTCCATCTCCAGGGAAAATATTTAGACG... | CCCAGTCCTACACGGCTGATTTCTCTGGTGAAGGGATCCGGGCAGTGTCTTAGGAACTGCTCAAAGTTCCCAGATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCTTTCCATCTCCAGGGAAAATATTTAGACG... |
Task1_train_3111 | This mutation occurs in SOX11 (SRY-box transcription factor 11) on Chromosome 2. Does this change lead to a known medical condition, or is it benign? | Pathogenic; not provided | CGGCTGATTTCTCTGGTGAAGGGATCCGGGCAGTGTCTTAGGAACTGCTCAAAGTTCCCAGATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCTTTCCATCTCCAGGGAAAATATTTAGACGGGAAACTCGAGT... | CGGCTGATTTCTCTGGTGAAGGGATCCGGGCAGTGTCTTAGGAACTGCTCAAAGTTCCCAGATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCTTTCCATCTCCAGGGAAAATATTTAGACGGGAAACTCGAGT... |
Task1_train_3112 | A variant has been detected on Chromosome 2 in SOX11 (SRY-box transcription factor 11). What is its effect — pathogenic or benign? If pathogenic, name the disease. | Pathogenic; Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism | GATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCTTTCCATCTCCAGGGAAAATATTTAGACGGGAAACTCGAGTGCACCTTATTTTCTCTTTGGTTTATGAGTGACCCAGAAGGCTTCTAGCTCACAATCGCAC... | GATACCCAGTGCTGGGGGGTGTGGAGAAGGCGAGGGTGGCGACAGACCATACCTATGAAGCGGTGATTTTCTTTAATTGCCCCCAGAATATCCGTAGAGGTAGTAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCTTTCCATCTCCAGGGAAAATATTTAGACGGGAAACTCGAGTGCACCTTATTTTCTCTTTGGTTTATGAGTGACCCAGAAGGCTTCTAGCTCACAATCGCAC... |
Task1_train_3113 | A variant on Chromosome 2 in gene SOX11 (SRY-box transcription factor 11) has been observed. Is this a neutral mutation, or does it result in a disease? If so, which one? | Pathogenic; Intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism | TAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCTTTCCATCTCCAGGGAAAATATTTAGACGGGAAACTCGAGTGCACCTTATTTTCTCTTTGGTTTATGAGTGACCCAGAAGGCTTCTAGCTCACAATCGCACGATTTCAGGACGAGGCTGCCGGAGAAGCGCTGGCGACCGAGGATGGGGGAAGGACAAAGAGGAAGAGGAGGCCTGGGAAGGAGAAAGGAGCGGCGGAGGGGCG... | TAGGGACTCAATAAAGAAACACAAAGGAGACGAACACGGCACGATCGCCGGGGTCCGCGGCTGCTCTGCGAGGCCCAGCGCGCCCCAGGTCGCGGCTCCCCGGCCGCCAGCGCACCTTTCCATCTCCAGGGAAAATATTTAGACGGGAAACTCGAGTGCACCTTATTTTCTCTTTGGTTTATGAGTGACCCAGAAGGCTTCTAGCTCACAATCGCACGATTTCAGGACGAGGCTGCCGGAGAAGCGCTGGCGACCGAGGATGGGGGAAGGACAAAGAGGAAGAGGAGGCCTGGGAAGGAGAAAGGAGCGGCGGAGGGGCG... |
Task1_train_3114 | A variant affecting Chromosome 2, within the gene CPSF3 (cleavage and polyadenylation specific factor 3), has been observed. Determine if it's benign or associated with disease. | Pathogenic; not specified | ACTTGAACCTGAGAGGTTGAGGCTGCCATGAGCCATGATCATACCACTACCCTCAAGGCTAGTCGACAGCCTGGGTGTAAAACACAAACAAAAACAAACAATAATAGCATAATATGACTATACTTTTTTTTTAAGTGTTCAAAATCGGTTAACTCTTGGCAATTCTCTTTTGTAATTAGCACTCAATAAATCTGTTTGAAATATTAATAATACATTTTTAAAACCATCACAGAATTTTTTCTAGTACACTTTTCTAATACATTTAAATAAAAATGTATTATTTAGTGTCTTATTATGGTAGTAAGTTATAGACTTCAGTG... | ACTTGAACCTGAGAGGTTGAGGCTGCCATGAGCCATGATCATACCACTACCCTCAAGGCTAGTCGACAGCCTGGGTGTAAAACACAAACAAAAACAAACAATAATAGCATAATATGACTATACTTTTTTTTTAAGTGTTCAAAATCGGTTAACTCTTGGCAATTCTCTTTTGTAATTAGCACTCAATAAATCTGTTTGAAATATTAATAATACATTTTTAAAACCATCACAGAATTTTTTCTAGTACACTTTTCTAATACATTTAAATAAAAATGTATTATTTAGTGTCTTATTATGGTAGTAAGTTATAGACTTCAGTG... |
Task1_train_3115 | The gene CPSF3 (cleavage and polyadenylation specific factor 3), on Chromosome 2, contains a mutation. Does this mutation cause a disorder, or is it a benign change? | Pathogenic; Neurodevelopmental disorder with hypotonia, microcephaly, and seizures | TGGAGGAAAAAAAGAAATTAGCAAAACTTAGGGTATGAGGTTTTTGTTGTAAATAGTCGTAGTTACTCCTGAGTCTTACTGTCCACAAAACTTTTCAGGGGCCGATTTAATAGTATTTTTCTTATACCTGTAGAAAAATATACTCAGTTGAGAATCTAGAACTGTATTTCACATACTCTGCTGGTGGTGGATATGTGGGGAGAAAAAAAAAGTTTTGCAGTCAGACAGTTTAGAAGATGAATTGAACTGAGTTCAGGAAAAGTTGGGTTTCTTATCGGAGTGTTCTGTTTCTCACCCATAATTTTAATGATTTAAAATCA... | TGGAGGAAAAAAAGAAATTAGCAAAACTTAGGGTATGAGGTTTTTGTTGTAAATAGTCGTAGTTACTCCTGAGTCTTACTGTCCACAAAACTTTTCAGGGGCCGATTTAATAGTATTTTTCTTATACCTGTAGAAAAATATACTCAGTTGAGAATCTAGAACTGTATTTCACATACTCTGCTGGTGGTGGATATGTGGGGAGAAAAAAAAAGTTTTGCAGTCAGACAGTTTAGAAGATGAATTGAACTGAGTTCAGGAAAAGTTGGGTTTCTTATCGGAGTGTTCTGTTTCTCACCCATAATTTTAATGATTTAAAATCA... |
Task1_train_3116 | Given this variant in gene NBAS (NBAS subunit of NRZ tethering complex) on Chromosome 2, classify it as benign or pathogenic. Include the disorder it may cause if applicable. | Pathogenic; not provided | ATATAAGTTTAAAATAATTTTAGATGTGTTTATTTAAAAATAAGTACTTAAAAATTTATAAGTATAGATCACTTTTCCTTGAAGATTGTAATTTTACTCTACTTCTCCTAATTATGAACTGTAGTACTGTAAATGTTAGTAGGATAAAATCAAGATTGGTAAAGCCAATTTGTTTCCTGCAAAGCCTTCTATATTGTTCATACCATTATTTAACATTATTCATTAGACAGAAAAATAGGCATTCCAAAACACAAAATGAATAAAATTTCTTTCAAAATTTTAAGTTCTTCCCATTATCTTTTCAATGGGGGCTTTGCATT... | ATATAAGTTTAAAATAATTTTAGATGTGTTTATTTAAAAATAAGTACTTAAAAATTTATAAGTATAGATCACTTTTCCTTGAAGATTGTAATTTTACTCTACTTCTCCTAATTATGAACTGTAGTACTGTAAATGTTAGTAGGATAAAATCAAGATTGGTAAAGCCAATTTGTTTCCTGCAAAGCCTTCTATATTGTTCATACCATTATTTAACATTATTCATTAGACAGAAAAATAGGCATTCCAAAACACAAAATGAATAAAATTTCTTTCAAAATTTTAAGTTCTTCCCATTATCTTTTCAATGGGGGCTTTGCATT... |
Task1_train_3117 | A variant found in Chromosome 2 affects NBAS (NBAS subunit of NRZ tethering complex). Please analyze its biological impact: is it benign or pathogenic, and what condition might it cause? | Pathogenic; Infantile liver failure syndrome 2 | GTTTCTACTTACATCTGGTTTGGAATGCTGAAATATCTTCAGGGGAAATTTTAAGTCCCCTTTAGCTAAAGTTACTAAATATTCTTTTAATAGCTCATTAGCCACACCAGGCGACTGTTTCTCACAACGATGAAGAAAGGGAACCATCCACTGGTAGGCACTTGTCACATATTTATCCTCAGAACACTGAAAGTACAATCAAGCAAAACAGACAAACAAGAATGAAGTTAAACTAAATGCCTTATTATATCAGACAGCGAGTTCTAAAGCTTACAGGTCCTCAGACTGATGTTAAACAGTGCAAACCCAACACTCTAAAA... | GTTTCTACTTACATCTGGTTTGGAATGCTGAAATATCTTCAGGGGAAATTTTAAGTCCCCTTTAGCTAAAGTTACTAAATATTCTTTTAATAGCTCATTAGCCACACCAGGCGACTGTTTCTCACAACGATGAAGAAAGGGAACCATCCACTGGTAGGCACTTGTCACATATTTATCCTCAGAACACTGAAAGTACAATCAAGCAAAACAGACAAACAAGAATGAAGTTAAACTAAATGCCTTATTATATCAGACAGCGAGTTCTAAAGCTTACAGGTCCTCAGACTGATGTTAAACAGTGCAAACCCAACACTCTAAAA... |
Task1_train_3118 | This mutation occurs in LOC129933155, NBAS (ATAC-STARR-seq lymphoblastoid active region 15346| NBAS subunit of NRZ tethering complex) on Chromosome 2. Does this change lead to a known medical condition, or is it benign? | Pathogenic; Short stature-optic atrophy-Pelger-HuC+t anomaly syndrome | CCAGTTCAGCATACTCTATTGAGGCTGTAAGTTTTGCTCACAGGAAAAGTGGTCATATCTCCAAGGCCAATTCATTGACTATCTGTTGTGTATCTATACAGACAATGCTACTAACAAAACATACACAGATACGTAATTGCTATATTAAATAATTCCATTCCATAAGTATAGACTGAACACACCGTGGGTAGGTTCATGACGCTAGGCACTGCATAAGATGCACTAAAGTGCTGTCAAGAAAAGCACAATGGACATACAGTAAGTGTAGACAGATTTTTTTAAAAAACACAGAAAAGTTATTTCACTCAATAAACATGAAT... | CCAGTTCAGCATACTCTATTGAGGCTGTAAGTTTTGCTCACAGGAAAAGTGGTCATATCTCCAAGGCCAATTCATTGACTATCTGTTGTGTATCTATACAGACAATGCTACTAACAAAACATACACAGATACGTAATTGCTATATTAAATAATTCCATTCCATAAGTATAGACTGAACACACCGTGGGTAGGTTCATGACGCTAGGCACTGCATAAGATGCACTAAAGTGCTGTCAAGAAAAGCACAATGGACATACAGTAAGTGTAGACAGATTTTTTTAAAAAACACAGAAAAGTTATTTCACTCAATAAACATGAAT... |
Task1_train_3119 | This variant impacts the gene LOC129933155, NBAS (ATAC-STARR-seq lymphoblastoid active region 15346| NBAS subunit of NRZ tethering complex) on Chromosome 2. Is the change likely to result in a pathogenic outcome? | Pathogenic; Infantile liver failure syndrome 2 | CCAGTTCAGCATACTCTATTGAGGCTGTAAGTTTTGCTCACAGGAAAAGTGGTCATATCTCCAAGGCCAATTCATTGACTATCTGTTGTGTATCTATACAGACAATGCTACTAACAAAACATACACAGATACGTAATTGCTATATTAAATAATTCCATTCCATAAGTATAGACTGAACACACCGTGGGTAGGTTCATGACGCTAGGCACTGCATAAGATGCACTAAAGTGCTGTCAAGAAAAGCACAATGGACATACAGTAAGTGTAGACAGATTTTTTTAAAAAACACAGAAAAGTTATTTCACTCAATAAACATGAAT... | CCAGTTCAGCATACTCTATTGAGGCTGTAAGTTTTGCTCACAGGAAAAGTGGTCATATCTCCAAGGCCAATTCATTGACTATCTGTTGTGTATCTATACAGACAATGCTACTAACAAAACATACACAGATACGTAATTGCTATATTAAATAATTCCATTCCATAAGTATAGACTGAACACACCGTGGGTAGGTTCATGACGCTAGGCACTGCATAAGATGCACTAAAGTGCTGTCAAGAAAAGCACAATGGACATACAGTAAGTGTAGACAGATTTTTTTAAAAAACACAGAAAAGTTATTTCACTCAATAAACATGAAT... |
Task1_train_3120 | A variant affecting Chromosome 2, within the gene MYCN, MYCNOS (MYCN proto-oncogene, bHLH transcription factor| MYCN opposite strand), has been observed. Determine if it's benign or associated with disease. | Pathogenic; MYCN-related disorder | TTTTTTTTCTTTTAATGACAAGCAATTGCCAGGCTCGCAGGGTGGGTGCTGCATTGCACCGCTCCGCGCGCAGCTGGTTCTCAGAGTGCAGCCGGTGCAAGCCCGGGGGTCCAAAAGGGCGGGAGGAGCACACCCTGGGCTTCCCAGCTTTGCAGCCTTCTCTCTGCAAAGAAAAGCAAGTGGCTTTTGGCGCGAAAGCCTTGGCGCCTCCCCTGATTTTTATGGAAATCAGGAGGGCGGGGTAAAGCCGCTTTCCTCTCCTTTCTCCCTCCCCCTTGTCTGCGCCACAGCCCCCTTCTCTCCCCGCCCCCCGGGTGTGT... | TTTTTTTTCTTTTAATGACAAGCAATTGCCAGGCTCGCAGGGTGGGTGCTGCATTGCACCGCTCCGCGCGCAGCTGGTTCTCAGAGTGCAGCCGGTGCAAGCCCGGGGGTCCAAAAGGGCGGGAGGAGCACACCCTGGGCTTCCCAGCTTTGCAGCCTTCTCTCTGCAAAGAAAAGCAAGTGGCTTTTGGCGCGAAAGCCTTGGCGCCTCCCCTGATTTTTATGGAAATCAGGAGGGCGGGGTAAAGCCGCTTTCCTCTCCTTTCTCCCTCCCCCTTGTCTGCGCCACAGCCCCCTTCTCTCCCCGCCCCCCGGGTGTGT... |
Task1_train_3121 | Given this context: Chromosome 2, gene MYCN, MYCNOS (MYCN proto-oncogene, bHLH transcription factor| MYCN opposite strand) — does this variant present pathogenic behavior, and if so, what disease does it relate to? | Pathogenic; Megalencephaly-polydactyly syndrome | TTTTTTTTCTTTTAATGACAAGCAATTGCCAGGCTCGCAGGGTGGGTGCTGCATTGCACCGCTCCGCGCGCAGCTGGTTCTCAGAGTGCAGCCGGTGCAAGCCCGGGGGTCCAAAAGGGCGGGAGGAGCACACCCTGGGCTTCCCAGCTTTGCAGCCTTCTCTCTGCAAAGAAAAGCAAGTGGCTTTTGGCGCGAAAGCCTTGGCGCCTCCCCTGATTTTTATGGAAATCAGGAGGGCGGGGTAAAGCCGCTTTCCTCTCCTTTCTCCCTCCCCCTTGTCTGCGCCACAGCCCCCTTCTCTCCCCGCCCCCCGGGTGTGT... | TTTTTTTTCTTTTAATGACAAGCAATTGCCAGGCTCGCAGGGTGGGTGCTGCATTGCACCGCTCCGCGCGCAGCTGGTTCTCAGAGTGCAGCCGGTGCAAGCCCGGGGGTCCAAAAGGGCGGGAGGAGCACACCCTGGGCTTCCCAGCTTTGCAGCCTTCTCTCTGCAAAGAAAAGCAAGTGGCTTTTGGCGCGAAAGCCTTGGCGCCTCCCCTGATTTTTATGGAAATCAGGAGGGCGGGGTAAAGCCGCTTTCCTCTCCTTTCTCCCTCCCCCTTGTCTGCGCCACAGCCCCCTTCTCTCCCCGCCCCCCGGGTGTGT... |
Task1_train_3122 | This sequence variant lies in MYCN (MYCN proto-oncogene, bHLH transcription factor) on Chromosome 2. Is it clinically significant, and what condition might it cause if any? | Pathogenic; not provided | TGTGTTCATTTGTCTGTGTCTTAAGCTGAAGGGAAGAGTTAAAACCAAGCCTTTCCCTGGGGGTCTGGATGAACAGAACTCAACCCAAAGAGTGGCATTGCCTTGTCCTTGGAGCAGGGAGCTGGGACCCCCCTTGGACTTTGAAAACCAGTGTTTTCAGAATGCAGGTGGATAACAAGCCTAAATTTACTTCTGGGCTGAGGAGAGATCTTTGAGGCTCCTGGAAGGAAACTTGGTGATAAGCCTCCAGTTTGAAACGGCTCTGTCCCTTTAATGTCTGTGCCTTGACAGCTTTTGGTGAGGAAGCACTTCCTTCCAAC... | TGTGTTCATTTGTCTGTGTCTTAAGCTGAAGGGAAGAGTTAAAACCAAGCCTTTCCCTGGGGGTCTGGATGAACAGAACTCAACCCAAAGAGTGGCATTGCCTTGTCCTTGGAGCAGGGAGCTGGGACCCCCCTTGGACTTTGAAAACCAGTGTTTTCAGAATGCAGGTGGATAACAAGCCTAAATTTACTTCTGGGCTGAGGAGAGATCTTTGAGGCTCCTGGAAGGAAACTTGGTGATAAGCCTCCAGTTTGAAACGGCTCTGTCCCTTTAATGTCTGTGCCTTGACAGCTTTTGGTGAGGAAGCACTTCCTTCCAAC... |
Task1_train_3123 | This genomic variant is located on Chromosome 2, within the MYCN (MYCN proto-oncogene, bHLH transcription factor) gene. Can you determine its pathogenicity and name any linked disease? | Pathogenic; Feingold syndrome type 1 | GAAGAGTTAAAACCAAGCCTTTCCCTGGGGGTCTGGATGAACAGAACTCAACCCAAAGAGTGGCATTGCCTTGTCCTTGGAGCAGGGAGCTGGGACCCCCCTTGGACTTTGAAAACCAGTGTTTTCAGAATGCAGGTGGATAACAAGCCTAAATTTACTTCTGGGCTGAGGAGAGATCTTTGAGGCTCCTGGAAGGAAACTTGGTGATAAGCCTCCAGTTTGAAACGGCTCTGTCCCTTTAATGTCTGTGCCTTGACAGCTTTTGGTGAGGAAGCACTTCCTTCCAACAGCTGTCTTCTTGGCAGAAAACCAAAACATTG... | GAAGAGTTAAAACCAAGCCTTTCCCTGGGGGTCTGGATGAACAGAACTCAACCCAAAGAGTGGCATTGCCTTGTCCTTGGAGCAGGGAGCTGGGACCCCCCTTGGACTTTGAAAACCAGTGTTTTCAGAATGCAGGTGGATAACAAGCCTAAATTTACTTCTGGGCTGAGGAGAGATCTTTGAGGCTCCTGGAAGGAAACTTGGTGATAAGCCTCCAGTTTGAAACGGCTCTGTCCCTTTAATGTCTGTGCCTTGACAGCTTTTGGTGAGGAAGCACTTCCTTCCAACAGCTGTCTTCTTGGCAGAAAACCAAAACATTG... |
Task1_train_3124 | Given this variant in gene MYCN (MYCN proto-oncogene, bHLH transcription factor) on Chromosome 2, classify it as benign or pathogenic. Include the disorder it may cause if applicable. | Pathogenic; Feingold syndrome type 1 | AAGAGTTAAAACCAAGCCTTTCCCTGGGGGTCTGGATGAACAGAACTCAACCCAAAGAGTGGCATTGCCTTGTCCTTGGAGCAGGGAGCTGGGACCCCCCTTGGACTTTGAAAACCAGTGTTTTCAGAATGCAGGTGGATAACAAGCCTAAATTTACTTCTGGGCTGAGGAGAGATCTTTGAGGCTCCTGGAAGGAAACTTGGTGATAAGCCTCCAGTTTGAAACGGCTCTGTCCCTTTAATGTCTGTGCCTTGACAGCTTTTGGTGAGGAAGCACTTCCTTCCAACAGCTGTCTTCTTGGCAGAAAACCAAAACATTGG... | AAGAGTTAAAACCAAGCCTTTCCCTGGGGGTCTGGATGAACAGAACTCAACCCAAAGAGTGGCATTGCCTTGTCCTTGGAGCAGGGAGCTGGGACCCCCCTTGGACTTTGAAAACCAGTGTTTTCAGAATGCAGGTGGATAACAAGCCTAAATTTACTTCTGGGCTGAGGAGAGATCTTTGAGGCTCCTGGAAGGAAACTTGGTGATAAGCCTCCAGTTTGAAACGGCTCTGTCCCTTTAATGTCTGTGCCTTGACAGCTTTTGGTGAGGAAGCACTTCCTTCCAACAGCTGTCTTCTTGGCAGAAAACCAAAACATTGG... |
Task1_train_3125 | With a mutation on Chromosome 2 in gene MYCN (MYCN proto-oncogene, bHLH transcription factor), classify this variant as benign or pathogenic. Include the disease if it's pathogenic. | Pathogenic; Feingold syndrome | AGTTAAAACCAAGCCTTTCCCTGGGGGTCTGGATGAACAGAACTCAACCCAAAGAGTGGCATTGCCTTGTCCTTGGAGCAGGGAGCTGGGACCCCCCTTGGACTTTGAAAACCAGTGTTTTCAGAATGCAGGTGGATAACAAGCCTAAATTTACTTCTGGGCTGAGGAGAGATCTTTGAGGCTCCTGGAAGGAAACTTGGTGATAAGCCTCCAGTTTGAAACGGCTCTGTCCCTTTAATGTCTGTGCCTTGACAGCTTTTGGTGAGGAAGCACTTCCTTCCAACAGCTGTCTTCTTGGCAGAAAACCAAAACATTGGCTT... | AGTTAAAACCAAGCCTTTCCCTGGGGGTCTGGATGAACAGAACTCAACCCAAAGAGTGGCATTGCCTTGTCCTTGGAGCAGGGAGCTGGGACCCCCCTTGGACTTTGAAAACCAGTGTTTTCAGAATGCAGGTGGATAACAAGCCTAAATTTACTTCTGGGCTGAGGAGAGATCTTTGAGGCTCCTGGAAGGAAACTTGGTGATAAGCCTCCAGTTTGAAACGGCTCTGTCCCTTTAATGTCTGTGCCTTGACAGCTTTTGGTGAGGAAGCACTTCCTTCCAACAGCTGTCTTCTTGGCAGAAAACCAAAACATTGGCTT... |
Task1_train_3126 | The gene WDR35 (WD repeat domain 35), on Chromosome 2, contains a mutation. Does this mutation cause a disorder, or is it a benign change? | Pathogenic; Cranioectodermal dysplasia 2 | GCTGGAATTCATTGTGTTACATTTAGGTAAGTAAGTTAGTAACCTAGGAGACTTATTAGGCAAAGTTAATAGAGCGTGTATGTGTGACCACAGATAGAAAGGAGCAAGAGATACCAAATATTCATGAAGCACTAAAAATATGAAAAGCCACAAAGATACCAAATATTCATGATACACTAAGTATGCATGAGACATATAAAGCCTTCAGTATGTGTGAGAAGTTGATTCAATTACCCACTGGTGACACTCATTCTGGCCTGTCCTTACCCAAGAAATACAATAAAATTCATGACTGCTCAGCAGACTAATAGGCAAGCTAT... | GCTGGAATTCATTGTGTTACATTTAGGTAAGTAAGTTAGTAACCTAGGAGACTTATTAGGCAAAGTTAATAGAGCGTGTATGTGTGACCACAGATAGAAAGGAGCAAGAGATACCAAATATTCATGAAGCACTAAAAATATGAAAAGCCACAAAGATACCAAATATTCATGATACACTAAGTATGCATGAGACATATAAAGCCTTCAGTATGTGTGAGAAGTTGATTCAATTACCCACTGGTGACACTCATTCTGGCCTGTCCTTACCCAAGAAATACAATAAAATTCATGACTGCTCAGCAGACTAATAGGCAAGCTAT... |
Task1_train_3127 | Gene WDR35 (WD repeat domain 35) on Chromosome 2 is altered by this variant. Does this mutation result in a disease or is it benign? | Pathogenic; Cranioectodermal dysplasia 2 | TACCTTCAGAGGGTCACTGGAGATGAAAATGATCAAGCAGGGAATATCAACATTAAATATTCATCTCCTAATTCTCAAAGAAAATGTGCTTTATCAGTGAATTAAAACTTTGCACACAGATGGCATCTTTTTCTCTCAAATAATCTGAAGATTTACAGCTTAGATAAAGGTATGAATCTAGAATTCTTAACAACACTCAAATGGATAAAAATATATTGTTATTAGCTGTCAAACAATAACTTATCTCCTAAATAATAATATAGAATATTATGTCCTTAAGGAACATACTATTAAATATAATAGTATGTAAAACAGATCTT... | TACCTTCAGAGGGTCACTGGAGATGAAAATGATCAAGCAGGGAATATCAACATTAAATATTCATCTCCTAATTCTCAAAGAAAATGTGCTTTATCAGTGAATTAAAACTTTGCACACAGATGGCATCTTTTTCTCTCAAATAATCTGAAGATTTACAGCTTAGATAAAGGTATGAATCTAGAATTCTTAACAACACTCAAATGGATAAAAATATATTGTTATTAGCTGTCAAACAATAACTTATCTCCTAAATAATAATATAGAATATTATGTCCTTAAGGAACATACTATTAAATATAATAGTATGTAAAACAGATCTT... |
Task1_train_3128 | Mutation context: Chromosome 2, Gene WDR35 (WD repeat domain 35). Determine if this variant is likely to be benign or pathogenic. Mention the disease if applicable. | Pathogenic; Cranioectodermal dysplasia 2 | AAAGACTCTAACATTCAAAAAGTATTCTACTCCCATCCTCAAGGTTATCCTGTGGATTACCTGTCAAATTCCCACAATTGTTTTGTGGCAAGGATTAAATTTCCCTTGGACCCTTGAAAGAAGCCCATGCTTACAGGTCAAATGCAGCAGCCCTGAATCTGAATGCCTTTCCTTTGAACTATTTCTCAGGGTCGAAGAATCACAAAGATCCTAAGACTTGCAAAAGCTTTAACAGAGCCTTTGAGAGCACTTTACATCAGGGCATTTTACATCCAAAATTCCTGAGTAGGGCTCAAATGGGGAAATGTGAAAATAATTTA... | AAAGACTCTAACATTCAAAAAGTATTCTACTCCCATCCTCAAGGTTATCCTGTGGATTACCTGTCAAATTCCCACAATTGTTTTGTGGCAAGGATTAAATTTCCCTTGGACCCTTGAAAGAAGCCCATGCTTACAGGTCAAATGCAGCAGCCCTGAATCTGAATGCCTTTCCTTTGAACTATTTCTCAGGGTCGAAGAATCACAAAGATCCTAAGACTTGCAAAAGCTTTAACAGAGCCTTTGAGAGCACTTTACATCAGGGCATTTTACATCCAAAATTCCTGAGTAGGGCTCAAATGGGGAAATGTGAAAATAATTTA... |
Task1_train_3129 | Consider a variant on Chromosome 2 in gene WDR35 (WD repeat domain 35). Determine its clinical classification and disease relevance. | Pathogenic; Short-rib thoracic dysplasia 7 with or without polydactyly | CATTTTCCCAAGGAAACCAATGGAAGAAAAAAACTCAAAGTTTTAACCTAGGAGGGTCTGATCTATCTGTCTTGCTACCTGTATGAAATTAAAGGTGAACCAGCAAGCCCTCTACAGTACTCTTGGTATTGACCCATCCATAAGAGGAGGAGAATACGACCATCTTCTAACTGCAAACCAGCCAGGATGTGGCAGCAGCAAGGAAAGAAAACCACCTTTTAGTAAGCCCTCATTACATGCCAGGCACTGTGTAGGCATTTCCTCATTGTAATCTCCTTTAATCTTTACAACAGCACCATGACGTATTTCCTTTATTTCTG... | CATTTTCCCAAGGAAACCAATGGAAGAAAAAAACTCAAAGTTTTAACCTAGGAGGGTCTGATCTATCTGTCTTGCTACCTGTATGAAATTAAAGGTGAACCAGCAAGCCCTCTACAGTACTCTTGGTATTGACCCATCCATAAGAGGAGGAGAATACGACCATCTTCTAACTGCAAACCAGCCAGGATGTGGCAGCAGCAAGGAAAGAAAACCACCTTTTAGTAAGCCCTCATTACATGCCAGGCACTGTGTAGGCATTTCCTCATTGTAATCTCCTTTAATCTTTACAACAGCACCATGACGTATTTCCTTTATTTCTG... |
Task1_train_3130 | Gene WDR35 (WD repeat domain 35) on Chromosome 2 is impacted by this variant. Evaluate whether it is clinically benign or pathogenic and name the disorder if relevant. | Pathogenic; not provided | GGCAACCAACAAAAATAACCAATAAAGAACAAGAATTAAGAAGGAGGCTATAAATATAGAAATAATTAGAATGCAGATTTTTAATTATTTAGGAACCTTGAAAACTATGCTTTTTTTTTTCCTTCACTTTTACATCTACGAGAAATATTGTCGTTTGACAATGTATAGAGAGCATCTACGTTCTACAGTATATTCTACTGGGTAACTTTGAGATACTGATTCAAAAGCATCAGAAGACATCATTTCTTGCCCTAAAAGAAATTATTAAAATATATAAAAATAACATTAAAACAACTGGTATAGGCTTTTATGCAGCCAAA... | GGCAACCAACAAAAATAACCAATAAAGAACAAGAATTAAGAAGGAGGCTATAAATATAGAAATAATTAGAATGCAGATTTTTAATTATTTAGGAACCTTGAAAACTATGCTTTTTTTTTTCCTTCACTTTTACATCTACGAGAAATATTGTCGTTTGACAATGTATAGAGAGCATCTACGTTCTACAGTATATTCTACTGGGTAACTTTGAGATACTGATTCAAAAGCATCAGAAGACATCATTTCTTGCCCTAAAAGAAATTATTAAAATATATAAAAATAACATTAAAACAACTGGTATAGGCTTTTATGCAGCCAAA... |
Task1_train_3131 | This genomic variant is located on Chromosome 2, within the WDR35 (WD repeat domain 35) gene. Can you determine its pathogenicity and name any linked disease? | Pathogenic; Cranioectodermal dysplasia 2 | GTAGAAGCTATTCTTCTGCTAAGAGTCTAAGTTCATTTTGGAGATGGCCAACAGTCACCTAATTCACTTTCTTAATAACAGGGTTAAAGTTTTAAAAAAGTGAAAAGTAGGCAGCAATAAATCCAGAAATATTATCACTGTGCAGTCAGGATGAACTCCTGTTGTTAGTAAAAGGGGTCTATTTTGGAGATGTTATTTACCCATCCAAATACTGTGATCCAGATGCCAACTTGTGAAAAATTAAATAATCTCTCCTAGTAAAGTATACCTTTATATAACATCCACACAATGATAAGCCCGTTTTCATCACTGGTAGTCAA... | GTAGAAGCTATTCTTCTGCTAAGAGTCTAAGTTCATTTTGGAGATGGCCAACAGTCACCTAATTCACTTTCTTAATAACAGGGTTAAAGTTTTAAAAAAGTGAAAAGTAGGCAGCAATAAATCCAGAAATATTATCACTGTGCAGTCAGGATGAACTCCTGTTGTTAGTAAAAGGGGTCTATTTTGGAGATGTTATTTACCCATCCAAATACTGTGATCCAGATGCCAACTTGTGAAAAATTAAATAATCTCTCCTAGTAAAGTATACCTTTATATAACATCCACACAATGATAAGCCCGTTTTCATCACTGGTAGTCAA... |
Task1_train_3132 | This sequence variant lies in WDR35 (WD repeat domain 35) on Chromosome 2. Is it clinically significant, and what condition might it cause if any? | Pathogenic; WDR35-related disorder | GTAGAAGCTATTCTTCTGCTAAGAGTCTAAGTTCATTTTGGAGATGGCCAACAGTCACCTAATTCACTTTCTTAATAACAGGGTTAAAGTTTTAAAAAAGTGAAAAGTAGGCAGCAATAAATCCAGAAATATTATCACTGTGCAGTCAGGATGAACTCCTGTTGTTAGTAAAAGGGGTCTATTTTGGAGATGTTATTTACCCATCCAAATACTGTGATCCAGATGCCAACTTGTGAAAAATTAAATAATCTCTCCTAGTAAAGTATACCTTTATATAACATCCACACAATGATAAGCCCGTTTTCATCACTGGTAGTCAA... | GTAGAAGCTATTCTTCTGCTAAGAGTCTAAGTTCATTTTGGAGATGGCCAACAGTCACCTAATTCACTTTCTTAATAACAGGGTTAAAGTTTTAAAAAAGTGAAAAGTAGGCAGCAATAAATCCAGAAATATTATCACTGTGCAGTCAGGATGAACTCCTGTTGTTAGTAAAAGGGGTCTATTTTGGAGATGTTATTTACCCATCCAAATACTGTGATCCAGATGCCAACTTGTGAAAAATTAAATAATCTCTCCTAGTAAAGTATACCTTTATATAACATCCACACAATGATAAGCCCGTTTTCATCACTGGTAGTCAA... |
Task1_train_3133 | Given this variant in gene MATN3, WDR35-DT (matrilin 3| WDR35 divergent transcript) on Chromosome 2, classify it as benign or pathogenic. Include the disorder it may cause if applicable. | Pathogenic; Spondyloepimetaphyseal dysplasia, matrilin-3 type | AGATTTATGAAAAGGTTGCAAAAACAGTGCAAAAAATTCCTGTACTTCACCCTGTTTCCCCAAACAGTAATTTACATAACCATAGTATGATTATCAAACCAGAAATTAACATTGATATAATATGATTTACTAATCTACAGACTTTATTCAAATGTTGCCATTAATGTCCTTTTTCTGGTCCAGGATCCAATCCAGGATTCCACATTGCATTCAGTTTCACATCTCCGTCCTCTCCAACCTGGGACACTTCCTAAGTCTTTCTTTGTCTTTTATGACTTTCACGTTTCTGAGAAGTACTGGAAAACTATTTTGTGAACTGA... | AGATTTATGAAAAGGTTGCAAAAACAGTGCAAAAAATTCCTGTACTTCACCCTGTTTCCCCAAACAGTAATTTACATAACCATAGTATGATTATCAAACCAGAAATTAACATTGATATAATATGATTTACTAATCTACAGACTTTATTCAAATGTTGCCATTAATGTCCTTTTTCTGGTCCAGGATCCAATCCAGGATTCCACATTGCATTCAGTTTCACATCTCCGTCCTCTCCAACCTGGGACACTTCCTAAGTCTTTCTTTGTCTTTTATGACTTTCACGTTTCTGAGAAGTACTGGAAAACTATTTTGTGAACTGA... |
Task1_train_3134 | A mutation on Chromosome 2 affecting MATN3 (matrilin 3) has been found. Is it harmful or harmless? What disease, if any, does it cause? | Pathogenic; not provided | TCGGGTAACTGTCTTCTGAATATGTAAGGTGGGTGAAGTCATCCATACGCTAAATCCATAGTGAACTCATATGCTAATACAAACAGGTAAAAAGAAAAGAACAAAATAAATGAGATTACATTAGCTAAACTACATCTCCATCTTATTGCTCCTGGAGCCATTTATATCTCATTGGATATTTTTTTCCTAGTGACCTCTTTTGAAAGATGAATCAATGAATTAAGTCATTTCTGAGAAACCAAGGAGGCCTGTTGAAGGAGGCTGGCCCTCCTGTGGCAGGTAACCCAACCTCCACTGCCCTTGGCAACAGGACAAGGCTA... | TCGGGTAACTGTCTTCTGAATATGTAAGGTGGGTGAAGTCATCCATACGCTAAATCCATAGTGAACTCATATGCTAATACAAACAGGTAAAAAGAAAAGAACAAAATAAATGAGATTACATTAGCTAAACTACATCTCCATCTTATTGCTCCTGGAGCCATTTATATCTCATTGGATATTTTTTTCCTAGTGACCTCTTTTGAAAGATGAATCAATGAATTAAGTCATTTCTGAGAAACCAAGGAGGCCTGTTGAAGGAGGCTGGCCCTCCTGTGGCAGGTAACCCAACCTCCACTGCCCTTGGCAACAGGACAAGGCTA... |
Task1_train_3135 | This sequence change occurs on Chromosome 2, altering MATN3 (matrilin 3). What is the medical significance of this variant — is it benign or linked to a disease? | Pathogenic; Multiple epiphyseal dysplasia type 5 | AATACAAACAGGTAAAAAGAAAAGAACAAAATAAATGAGATTACATTAGCTAAACTACATCTCCATCTTATTGCTCCTGGAGCCATTTATATCTCATTGGATATTTTTTTCCTAGTGACCTCTTTTGAAAGATGAATCAATGAATTAAGTCATTTCTGAGAAACCAAGGAGGCCTGTTGAAGGAGGCTGGCCCTCCTGTGGCAGGTAACCCAACCTCCACTGCCCTTGGCAACAGGACAAGGCTAATATTTTCCCAAGAAGGGCCTTTTCATGGAATGATCTTTCCAACCCGTTGACTACAACAAGCTGCCGCTCAGTCT... | AATACAAACAGGTAAAAAGAAAAGAACAAAATAAATGAGATTACATTAGCTAAACTACATCTCCATCTTATTGCTCCTGGAGCCATTTATATCTCATTGGATATTTTTTTCCTAGTGACCTCTTTTGAAAGATGAATCAATGAATTAAGTCATTTCTGAGAAACCAAGGAGGCCTGTTGAAGGAGGCTGGCCCTCCTGTGGCAGGTAACCCAACCTCCACTGCCCTTGGCAACAGGACAAGGCTAATATTTTCCCAAGAAGGGCCTTTTCATGGAATGATCTTTCCAACCCGTTGACTACAACAAGCTGCCGCTCAGTCT... |
Task1_train_3136 | Here’s a variant in MATN3 (matrilin 3) located on Chromosome 2. What is the predicted biological effect — harmless or disease-causing? | Pathogenic; Multiple epiphyseal dysplasia type 5 | GGCAGGTAACCCAACCTCCACTGCCCTTGGCAACAGGACAAGGCTAATATTTTCCCAAGAAGGGCCTTTTCATGGAATGATCTTTCCAACCCGTTGACTACAACAAGCTGCCGCTCAGTCTTTTTTCCATAGAGAGGACGTTTTTCCCCCAGAACAAGCAGGTCTTTTGTACCAGAAGGAAAAGATTGCCACTCACCACTTGTTACTTTATAGCCTTCGAAGCCCAACCCCAGGTGCTAGCTTTGAAACCCAACTTTGCCACAGACCAGCATGTTGATGGAGAGGCTCTCACCCACAAGCATGGAGTGGGAGGGTGATTT... | GGCAGGTAACCCAACCTCCACTGCCCTTGGCAACAGGACAAGGCTAATATTTTCCCAAGAAGGGCCTTTTCATGGAATGATCTTTCCAACCCGTTGACTACAACAAGCTGCCGCTCAGTCTTTTTTCCATAGAGAGGACGTTTTTCCCCCAGAACAAGCAGGTCTTTTGTACCAGAAGGAAAAGATTGCCACTCACCACTTGTTACTTTATAGCCTTCGAAGCCCAACCCCAGGTGCTAGCTTTGAAACCCAACTTTGCCACAGACCAGCATGTTGATGGAGAGGCTCTCACCCACAAGCATGGAGTGGGAGGGTGATTT... |
Task1_train_3137 | Located on Chromosome 2, this mutation impacts APOB (apolipoprotein B). What is its biological consequence — is it benign or pathogenic, and which disease is associated if any? | Pathogenic; Hypercholesterolemia, familial, 1 | CTTTCTAGAGCTCAGCTTGGAGGCTCTGACTGGATATTGCCAGTGTTTAAAATCAGAGTTTGAAGTGAGTGGATGTGGCAGGAGAAACCCTTGGGTTTTTACTACACTTGGGATTGTTGGATATTATATTTGGAAAAATAAGGATGCTTAAGAGCCTAAAGAGCATACATGTATGCTGGGTCACAGAATTGTTAGGAATCTACATCTCCACCCCTCCTCTCCCAATCATACTTTCTTGGCCTTGAATGGATCCTGGCAGAGCTCCAGGGAGACATCTGGGGTCCGTATTGCCATGAAGCCCCTGGGGCTAGGACTCCCTA... | CTTTCTAGAGCTCAGCTTGGAGGCTCTGACTGGATATTGCCAGTGTTTAAAATCAGAGTTTGAAGTGAGTGGATGTGGCAGGAGAAACCCTTGGGTTTTTACTACACTTGGGATTGTTGGATATTATATTTGGAAAAATAAGGATGCTTAAGAGCCTAAAGAGCATACATGTATGCTGGGTCACAGAATTGTTAGGAATCTACATCTCCACCCCTCCTCTCCCAATCATACTTTCTTGGCCTTGAATGGATCCTGGCAGAGCTCCAGGGAGACATCTGGGGTCCGTATTGCCATGAAGCCCCTGGGGCTAGGACTCCCTA... |
Task1_train_3138 | A mutation in APOB (apolipoprotein B), located on Chromosome 2, is being studied. Determine whether it’s pathogenic or benign, and specify the linked disease. | Pathogenic; Cardiovascular phenotype | TGGATGTGGCAGGAGAAACCCTTGGGTTTTTACTACACTTGGGATTGTTGGATATTATATTTGGAAAAATAAGGATGCTTAAGAGCCTAAAGAGCATACATGTATGCTGGGTCACAGAATTGTTAGGAATCTACATCTCCACCCCTCCTCTCCCAATCATACTTTCTTGGCCTTGAATGGATCCTGGCAGAGCTCCAGGGAGACATCTGGGGTCCGTATTGCCATGAAGCCCCTGGGGCTAGGACTCCCTAGCCATTCCTTCTCCACTCCTGGCAGGCTGAGTGAAATAAAGGACTTGTTATTTCATCTCGAGGCCTACC... | TGGATGTGGCAGGAGAAACCCTTGGGTTTTTACTACACTTGGGATTGTTGGATATTATATTTGGAAAAATAAGGATGCTTAAGAGCCTAAAGAGCATACATGTATGCTGGGTCACAGAATTGTTAGGAATCTACATCTCCACCCCTCCTCTCCCAATCATACTTTCTTGGCCTTGAATGGATCCTGGCAGAGCTCCAGGGAGACATCTGGGGTCCGTATTGCCATGAAGCCCCTGGGGCTAGGACTCCCTAGCCATTCCTTCTCCACTCCTGGCAGGCTGAGTGAAATAAAGGACTTGTTATTTCATCTCGAGGCCTACC... |
Task1_train_3139 | A mutation on Chromosome 2 affecting APOB (apolipoprotein B) has been found. Is it harmful or harmless? What disease, if any, does it cause? | Pathogenic; Hypercholesterolemia, familial, 1 | AGTGCTGATGGGATGTCATGTGTGCATCTAAACATTAAAATCAATCAAGGACTCATTGTAATACTTTCTAGAGAATATTTCCTCAGAGAAGAAGTTGCTTACCGCCTGTCTTTCACCTAGTTTGGGGAATCTCTGAATATTTGGTCCTGAATTAAATGTATCTGCCCCAATTCTCCACTCGCTCTTGGGGGCGTGTCACTCATTAGGTGGTATTTACCTGAGGGCTGTAGTAGAAGTTCCATTTAGAAAAGTCGTCATCTTCATCCATATCCATGCCCACGGTGCCTACGGCTGGGGAGGCTGCTGAGGTGGAGATGCCT... | AGTGCTGATGGGATGTCATGTGTGCATCTAAACATTAAAATCAATCAAGGACTCATTGTAATACTTTCTAGAGAATATTTCCTCAGAGAAGAAGTTGCTTACCGCCTGTCTTTCACCTAGTTTGGGGAATCTCTGAATATTTGGTCCTGAATTAAATGTATCTGCCCCAATTCTCCACTCGCTCTTGGGGGCGTGTCACTCATTAGGTGGTATTTACCTGAGGGCTGTAGTAGAAGTTCCATTTAGAAAAGTCGTCATCTTCATCCATATCCATGCCCACGGTGCCTACGGCTGGGGAGGCTGCTGAGGTGGAGATGCCT... |
Task1_train_3140 | The gene APOB (apolipoprotein B), on Chromosome 2, contains a mutation. Does this mutation cause a disorder, or is it a benign change? | Pathogenic; Familial hypobetalipoproteinemia 1 | GGGCGTGTCACTCATTAGGTGGTATTTACCTGAGGGCTGTAGTAGAAGTTCCATTTAGAAAAGTCGTCATCTTCATCCATATCCATGCCCACGGTGCCTACGGCTGGGGAGGCTGCTGAGGTGGAGATGCCTTTCTTGTCTTTCTGGTAGCGCAGATGGAGATCGGTGAACGCTGGGCTTTTGATATTGAGGTGCGCTTTTCCTTCCCATTCCCTGAAAGCAGAAAAACAGATGAGCTATCACGAAAGGGGTATGGAGATGAAGAAAATCACAATGAGTTTTCAAAAGGTATAAGGTTTCAATTCAATAAAAGCTCCATA... | GGGCGTGTCACTCATTAGGTGGTATTTACCTGAGGGCTGTAGTAGAAGTTCCATTTAGAAAAGTCGTCATCTTCATCCATATCCATGCCCACGGTGCCTACGGCTGGGGAGGCTGCTGAGGTGGAGATGCCTTTCTTGTCTTTCTGGTAGCGCAGATGGAGATCGGTGAACGCTGGGCTTTTGATATTGAGGTGCGCTTTTCCTTCCCATTCCCTGAAAGCAGAAAAACAGATGAGCTATCACGAAAGGGGTATGGAGATGAAGAAAATCACAATGAGTTTTCAAAAGGTATAAGGTTTCAATTCAATAAAAGCTCCATA... |
Task1_train_3141 | Gene APOB (apolipoprotein B) on Chromosome 2 is altered by this variant. Does this mutation result in a disease or is it benign? | Pathogenic; Hypercholesterolemia, autosomal dominant, type B | GGGCGTGTCACTCATTAGGTGGTATTTACCTGAGGGCTGTAGTAGAAGTTCCATTTAGAAAAGTCGTCATCTTCATCCATATCCATGCCCACGGTGCCTACGGCTGGGGAGGCTGCTGAGGTGGAGATGCCTTTCTTGTCTTTCTGGTAGCGCAGATGGAGATCGGTGAACGCTGGGCTTTTGATATTGAGGTGCGCTTTTCCTTCCCATTCCCTGAAAGCAGAAAAACAGATGAGCTATCACGAAAGGGGTATGGAGATGAAGAAAATCACAATGAGTTTTCAAAAGGTATAAGGTTTCAATTCAATAAAAGCTCCATA... | GGGCGTGTCACTCATTAGGTGGTATTTACCTGAGGGCTGTAGTAGAAGTTCCATTTAGAAAAGTCGTCATCTTCATCCATATCCATGCCCACGGTGCCTACGGCTGGGGAGGCTGCTGAGGTGGAGATGCCTTTCTTGTCTTTCTGGTAGCGCAGATGGAGATCGGTGAACGCTGGGCTTTTGATATTGAGGTGCGCTTTTCCTTCCCATTCCCTGAAAGCAGAAAAACAGATGAGCTATCACGAAAGGGGTATGGAGATGAAGAAAATCACAATGAGTTTTCAAAAGGTATAAGGTTTCAATTCAATAAAAGCTCCATA... |
Task1_train_3142 | This alteration occurs within gene APOB (apolipoprotein B) located on Chromosome 2. Is it associated with a disease or is it a benign variant? | Pathogenic; Familial hypobetalipoproteinemia 1 | GGCTAACGTACCATCTTCGATTTTGTGTGTTCCCAAAACTGTATAGGAGAGATTTTGTATTTTATTAGATTCATAACAGTAGGACGTTGATGTTTTCATTGTGAAAACTGGGAGAATTCTATCCTAACCAGATATTTCACTTGTGTTTAAAATATGCAATGTACAGCTCACACTTATTTTAAAATAAATAGTTAAAAGACATTGTTAGTCCTAAAATAATTACAGAAAAATCCATTTTCTTTAAAGCTGTTTGTCTTGAATGACACTAGATTTTCTACAGTTTGGTTTTTACGTGTAGGGTATACATGTATCTCTTTTCT... | GGCTAACGTACCATCTTCGATTTTGTGTGTTCCCAAAACTGTATAGGAGAGATTTTGTATTTTATTAGATTCATAACAGTAGGACGTTGATGTTTTCATTGTGAAAACTGGGAGAATTCTATCCTAACCAGATATTTCACTTGTGTTTAAAATATGCAATGTACAGCTCACACTTATTTTAAAATAAATAGTTAAAAGACATTGTTAGTCCTAAAATAATTACAGAAAAATCCATTTTCTTTAAAGCTGTTTGTCTTGAATGACACTAGATTTTCTACAGTTTGGTTTTTACGTGTAGGGTATACATGTATCTCTTTTCT... |
Task1_train_3143 | A change on Chromosome 2 affects gene APOB (apolipoprotein B). Identify whether the variant is neutral or disease-linked. Mention the disease if applicable. | Pathogenic; Hypercholesterolemia, autosomal dominant, type B | GGCTAACGTACCATCTTCGATTTTGTGTGTTCCCAAAACTGTATAGGAGAGATTTTGTATTTTATTAGATTCATAACAGTAGGACGTTGATGTTTTCATTGTGAAAACTGGGAGAATTCTATCCTAACCAGATATTTCACTTGTGTTTAAAATATGCAATGTACAGCTCACACTTATTTTAAAATAAATAGTTAAAAGACATTGTTAGTCCTAAAATAATTACAGAAAAATCCATTTTCTTTAAAGCTGTTTGTCTTGAATGACACTAGATTTTCTACAGTTTGGTTTTTACGTGTAGGGTATACATGTATCTCTTTTCT... | GGCTAACGTACCATCTTCGATTTTGTGTGTTCCCAAAACTGTATAGGAGAGATTTTGTATTTTATTAGATTCATAACAGTAGGACGTTGATGTTTTCATTGTGAAAACTGGGAGAATTCTATCCTAACCAGATATTTCACTTGTGTTTAAAATATGCAATGTACAGCTCACACTTATTTTAAAATAAATAGTTAAAAGACATTGTTAGTCCTAAAATAATTACAGAAAAATCCATTTTCTTTAAAGCTGTTTGTCTTGAATGACACTAGATTTTCTACAGTTTGGTTTTTACGTGTAGGGTATACATGTATCTCTTTTCT... |
Task1_train_3144 | This mutation occurs in APOB (apolipoprotein B) on Chromosome 2. Does this change lead to a known medical condition, or is it benign? | Pathogenic; APOB-related disorder | TCCAAAGGCAGTGAGGGTAGTTTTCAGCATGCTTTCTTTAGGAAGGTAGTTATTTGGATCAAATATAAGATTCCCTTCTATTTTGGCTGAGGCTGGGTCAAGTGATGGAAGAGAAACAGATTTGTAGAGTTGATAGTTCCGAGAGAATTTTCTGAAGTCCATGACAGTTGGAAGTTGAGATTCTTTCAGAGCTTCTTTCACTAACTTTTTCAGACTAGATAAGAAGAAGTATATTTTGAGCTGACACACCATGTTATTATCCTTTGACTCTTGCACCCCAAGTAAATATGGATTTCCAATCACTACCAAAATGTCTTGAT... | TCCAAAGGCAGTGAGGGTAGTTTTCAGCATGCTTTCTTTAGGAAGGTAGTTATTTGGATCAAATATAAGATTCCCTTCTATTTTGGCTGAGGCTGGGTCAAGTGATGGAAGAGAAACAGATTTGTAGAGTTGATAGTTCCGAGAGAATTTTCTGAAGTCCATGACAGTTGGAAGTTGAGATTCTTTCAGAGCTTCTTTCACTAACTTTTTCAGACTAGATAAGAAGAAGTATATTTTGAGCTGACACACCATGTTATTATCCTTTGACTCTTGCACCCCAAGTAAATATGGATTTCCAATCACTACCAAAATGTCTTGAT... |
Task1_train_3145 | This alteration in APOB (apolipoprotein B) on Chromosome 2 may affect gene function. Does it lead to a disease or is it benign? | Pathogenic; Hypercholesterolemia, autosomal dominant, type B | TCCAAAGGCAGTGAGGGTAGTTTTCAGCATGCTTTCTTTAGGAAGGTAGTTATTTGGATCAAATATAAGATTCCCTTCTATTTTGGCTGAGGCTGGGTCAAGTGATGGAAGAGAAACAGATTTGTAGAGTTGATAGTTCCGAGAGAATTTTCTGAAGTCCATGACAGTTGGAAGTTGAGATTCTTTCAGAGCTTCTTTCACTAACTTTTTCAGACTAGATAAGAAGAAGTATATTTTGAGCTGACACACCATGTTATTATCCTTTGACTCTTGCACCCCAAGTAAATATGGATTTCCAATCACTACCAAAATGTCTTGAT... | TCCAAAGGCAGTGAGGGTAGTTTTCAGCATGCTTTCTTTAGGAAGGTAGTTATTTGGATCAAATATAAGATTCCCTTCTATTTTGGCTGAGGCTGGGTCAAGTGATGGAAGAGAAACAGATTTGTAGAGTTGATAGTTCCGAGAGAATTTTCTGAAGTCCATGACAGTTGGAAGTTGAGATTCTTTCAGAGCTTCTTTCACTAACTTTTTCAGACTAGATAAGAAGAAGTATATTTTGAGCTGACACACCATGTTATTATCCTTTGACTCTTGCACCCCAAGTAAATATGGATTTCCAATCACTACCAAAATGTCTTGAT... |
Task1_train_3146 | This variant affects gene APOB (apolipoprotein B) located on Chromosome 2. Evaluate its biological effect and specify any disease association. | Pathogenic; Hypercholesterolemia, autosomal dominant, type B | TCCAAAGGCAGTGAGGGTAGTTTTCAGCATGCTTTCTTTAGGAAGGTAGTTATTTGGATCAAATATAAGATTCCCTTCTATTTTGGCTGAGGCTGGGTCAAGTGATGGAAGAGAAACAGATTTGTAGAGTTGATAGTTCCGAGAGAATTTTCTGAAGTCCATGACAGTTGGAAGTTGAGATTCTTTCAGAGCTTCTTTCACTAACTTTTTCAGACTAGATAAGAAGAAGTATATTTTGAGCTGACACACCATGTTATTATCCTTTGACTCTTGCACCCCAAGTAAATATGGATTTCCAATCACTACCAAAATGTCTTGAT... | TCCAAAGGCAGTGAGGGTAGTTTTCAGCATGCTTTCTTTAGGAAGGTAGTTATTTGGATCAAATATAAGATTCCCTTCTATTTTGGCTGAGGCTGGGTCAAGTGATGGAAGAGAAACAGATTTGTAGAGTTGATAGTTCCGAGAGAATTTTCTGAAGTCCATGACAGTTGGAAGTTGAGATTCTTTCAGAGCTTCTTTCACTAACTTTTTCAGACTAGATAAGAAGAAGTATATTTTGAGCTGACACACCATGTTATTATCCTTTGACTCTTGCACCCCAAGTAAATATGGATTTCCAATCACTACCAAAATGTCTTGAT... |
Task1_train_3147 | A genomic change on Chromosome 2 affects APOB (apolipoprotein B). Classify this variant as benign or pathogenic, and name the disease if relevant. | Pathogenic; Familial hypobetalipoproteinemia 1 | TCCAAAGGCAGTGAGGGTAGTTTTCAGCATGCTTTCTTTAGGAAGGTAGTTATTTGGATCAAATATAAGATTCCCTTCTATTTTGGCTGAGGCTGGGTCAAGTGATGGAAGAGAAACAGATTTGTAGAGTTGATAGTTCCGAGAGAATTTTCTGAAGTCCATGACAGTTGGAAGTTGAGATTCTTTCAGAGCTTCTTTCACTAACTTTTTCAGACTAGATAAGAAGAAGTATATTTTGAGCTGACACACCATGTTATTATCCTTTGACTCTTGCACCCCAAGTAAATATGGATTTCCAATCACTACCAAAATGTCTTGAT... | TCCAAAGGCAGTGAGGGTAGTTTTCAGCATGCTTTCTTTAGGAAGGTAGTTATTTGGATCAAATATAAGATTCCCTTCTATTTTGGCTGAGGCTGGGTCAAGTGATGGAAGAGAAACAGATTTGTAGAGTTGATAGTTCCGAGAGAATTTTCTGAAGTCCATGACAGTTGGAAGTTGAGATTCTTTCAGAGCTTCTTTCACTAACTTTTTCAGACTAGATAAGAAGAAGTATATTTTGAGCTGACACACCATGTTATTATCCTTTGACTCTTGCACCCCAAGTAAATATGGATTTCCAATCACTACCAAAATGTCTTGAT... |
Task1_train_3148 | This variant impacts the gene PTRHD1, LOC129933272 (peptidyl-tRNA hydrolase domain containing 1| ATAC-STARR-seq lymphoblastoid active region 15435) on Chromosome 2. Is the change likely to result in a pathogenic outcome? | Pathogenic; Parkinsonian disorder | TAAGCCTCCCAAAGTGCTAGGATTACAGGAGTGAGCCACCATGCCCGGCCCCTAGTGGAAGGATTTCTAAAAGCACATCCACTTCCACTTTCCTCCACCCCTCCCACTCTACCTCACTGAAACCTAGAGGGGTTTTCCTTCTGCTGGGATGGCTCCCACTTGTTTATTAAAGGGAGAGTACAATATTCTCTAACATCCTTCTGAAATTGTTTCTGGGTCATCCTTACTGCCAATTCACCCATGCTGAATCCCATTCCAGGAAGTATTAAAACGATCACTCAGAAAATTATTATTTTTGTGTTATTTTGCATAAAGTTTAT... | TAAGCCTCCCAAAGTGCTAGGATTACAGGAGTGAGCCACCATGCCCGGCCCCTAGTGGAAGGATTTCTAAAAGCACATCCACTTCCACTTTCCTCCACCCCTCCCACTCTACCTCACTGAAACCTAGAGGGGTTTTCCTTCTGCTGGGATGGCTCCCACTTGTTTATTAAAGGGAGAGTACAATATTCTCTAACATCCTTCTGAAATTGTTTCTGGGTCATCCTTACTGCCAATTCACCCATGCTGAATCCCATTCCAGGAAGTATTAAAACGATCACTCAGAAAATTATTATTTTTGTGTTATTTTGCATAAAGTTTAT... |
Task1_train_3149 | A genomic change on Chromosome 2 affects DNMT3A (DNA methyltransferase 3 alpha). Classify this variant as benign or pathogenic, and name the disease if relevant. | Pathogenic; not provided | TCCCATTATAAAATATATATCTCTATATGCCACATATCTACACCCCATCTACCCAGGCAAGCACCTGCCCGTCGGGCCCTCACCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGA... | TCCCATTATAAAATATATATCTCTATATGCCACATATCTACACCCCATCTACCCAGGCAAGCACCTGCCCGTCGGGCCCTCACCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGA... |
Task1_train_3150 | This alteration in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2 may affect gene function. Does it lead to a disease or is it benign? | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | TCTATATGCCACATATCTACACCCCATCTACCCAGGCAAGCACCTGCCCGTCGGGCCCTCACCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAA... | TCTATATGCCACATATCTACACCCCATCTACCCAGGCAAGCACCTGCCCGTCGGGCCCTCACCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAA... |
Task1_train_3151 | A genetic alteration is present in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Is this variant benign or disease-causing, and if the latter, which condition is involved? | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... |
Task1_train_3152 | This gene mutation involves DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Is it associated with any clinical condition, or is it benign? | Pathogenic; Neurodevelopmental disorder | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... |
Task1_train_3153 | A genetic alteration is present in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Is this variant benign or disease-causing, and if the latter, which condition is involved? | Pathogenic; Acute myeloid leukemia | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... |
Task1_train_3154 | This mutation occurs in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Does this change lead to a known medical condition, or is it benign? | Pathogenic; Inborn genetic diseases | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... |
Task1_train_3155 | Consider this mutation in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Is this a benign change or a disease-causing variant? | Pathogenic; Neoplasm | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... | CCCTGGAGCCAACAATGCCATCCCTTCCTACTACTGACGCCAGGCCGCCTGCCTTGTAGGAAGTAGAACAAAGTGTTGAGCACTTGGGGCTCCAGGTGCTGCTGACTCGAGGTAAGAGCACAGCTATCATCAGACCAAGTACTAGAAAAGAAATACACACCACTCCAATCACACACACAAGGAGAGAGACGGCCGGTCCTCCCTCCAGCCCTGACACACCCGACTCAAGAGGAGGGGAAGTAGAAGAGAAGAGTGACAAGCCCAGAAGGCAGACCTTGGGGACTCCCTGGCCGCCCAGCTGTCACCATGCCCAGTGGCCC... |
Task1_train_3156 | A mutation found in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2 may be clinically relevant. Is it pathogenic or benign, and if the former, which disease is implicated? | Pathogenic; Heyn-Sproul-Jackson syndrome | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... |
Task1_train_3157 | Mutation context: Chromosome 2, Gene DNMT3A (DNA methyltransferase 3 alpha). Determine if this variant is likely to be benign or pathogenic. Mention the disease if applicable. | Pathogenic; Acute myeloid leukemia | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... |
Task1_train_3158 | The following genetic variant occurs in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Classify its clinical effect — pathogenic or benign — and list any associated condition. | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... |
Task1_train_3159 | A sequence alteration has been identified in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Is it disease-inducing or harmless? | Pathogenic; Inborn genetic diseases | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... |
Task1_train_3160 | Assess the clinical impact of this variant on gene DNMT3A (DNA methyltransferase 3 alpha), found on Chromosome 2. State whether it’s pathogenic or benign, and the disease if applicable. | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... | CAACAAGCCCTCGATAGCAACTCTACCAAACATGTATGAGATGGGGAAGGTCCTACAACCTCATGGGAATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCT... |
Task1_train_3161 | This variant impacts the gene DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Is the change likely to result in a pathogenic outcome? | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | AATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCTTCATTCCTAGATATTAAAATCTTTATCTGTGTAACCTAACTGAAGAAAATCTCTCCAAAAAAGGACC... | AATAGCAAGGAGGGAGATTATTTGACCGAGGCCAGGTGAAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCTTCATTCCTAGATATTAAAATCTTTATCTGTGTAACCTAACTGAAGAAAATCTCTCCAAAAAAGGACC... |
Task1_train_3162 | Given this variant in gene DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2, classify it as benign or pathogenic. Include the disorder it may cause if applicable. | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | AAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCTTCATTCCTAGATATTAAAATCTTTATCTGTGTAACCTAACTGAAGAAAATCTCTCCAAAAAAGGACCTGAAGCCAACAAAGTGTGTGATTAGTAAAATTAAGTTA... | AAATGATGTCTCCTAGTTATACCAAGTATACCAAGCAGCCCACCATGGAGGTTTAACACCCATGACTCAGAACACTCTGGAAAACGCTTCCCTCCACAATGGACAGGGACTGAGCGGCTCTCAGCATGCTTTTGAATTGCCAACTCTGGACAATTTATTTCGCCTAAAAAGCCTTTTTATAATGCCAGTTTTATAACTGATGAAATGAATTTTCTTCATTCCTAGATATTAAAATCTTTATCTGTGTAACCTAACTGAAGAAAATCTCTCCAAAAAAGGACCTGAAGCCAACAAAGTGTGTGATTAGTAAAATTAAGTTA... |
Task1_train_3163 | Here is a genetic alteration in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Based on the data, is it a benign variant or a cause of disease? | Pathogenic; not provided | CTAACTGAAGAAAATCTCTCCAAAAAAGGACCTGAAGCCAACAAAGTGTGTGATTAGTAAAATTAAGTTAAGCAGAACCCTGAACTTGCATGCAGCCGCTGCAAGATTCCCTCTCCTGGAACAGGCTGTGGCCACAACTCCCCTTCCCAGCCCCAAAGCCATGCCCCATGGCTTTGCCTCAGGAGAATCTAAGAACCAGAGGGCTCGGGACACATCACCAATGTCAGAAAACCAACTACCTAACTCAGCAGCACAGGACTCTTCTTTGGTATAAAGAGAGTACTTTTAAAGGTCCTGCTTTAAGACCACTAGTTGTTGGT... | CTAACTGAAGAAAATCTCTCCAAAAAAGGACCTGAAGCCAACAAAGTGTGTGATTAGTAAAATTAAGTTAAGCAGAACCCTGAACTTGCATGCAGCCGCTGCAAGATTCCCTCTCCTGGAACAGGCTGTGGCCACAACTCCCCTTCCCAGCCCCAAAGCCATGCCCCATGGCTTTGCCTCAGGAGAATCTAAGAACCAGAGGGCTCGGGACACATCACCAATGTCAGAAAACCAACTACCTAACTCAGCAGCACAGGACTCTTCTTTGGTATAAAGAGAGTACTTTTAAAGGTCCTGCTTTAAGACCACTAGTTGTTGGT... |
Task1_train_3164 | This mutation is located in gene DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Is it associated with a disease or is it a benign polymorphism? | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | GGGTGTGTTTACCATGAGCCCTGATTAGAACTCAAACAGACGCCTGCTCACACTTACAGTCAGAACACCAGCTCACAGTGTGACCCACCCCAAGACTCAGGAGCACAGGTGGGCTCAAGCTCCCAGAAGGGCCACTCCAAGCACGCCTCTGGCAGCAGAAGCCCTCTGCACGCGGCTCAGACTTGGCTCAGGGTTAAACGGGGACTCACATGATAAGGAATGAAAACTGAGCTAAGTCTTGTTTTCTTCTCAGGTGCCTGTCATGGTACCAGGGAGTGAGGATAGGCCCTTCTTGCTCAGGGAAAACTGATTTTGTCCTC... | GGGTGTGTTTACCATGAGCCCTGATTAGAACTCAAACAGACGCCTGCTCACACTTACAGTCAGAACACCAGCTCACAGTGTGACCCACCCCAAGACTCAGGAGCACAGGTGGGCTCAAGCTCCCAGAAGGGCCACTCCAAGCACGCCTCTGGCAGCAGAAGCCCTCTGCACGCGGCTCAGACTTGGCTCAGGGTTAAACGGGGACTCACATGATAAGGAATGAAAACTGAGCTAAGTCTTGTTTTCTTCTCAGGTGCCTGTCATGGTACCAGGGAGTGAGGATAGGCCCTTCTTGCTCAGGGAAAACTGATTTTGTCCTC... |
Task1_train_3165 | Here’s a variant in DNMT3A (DNA methyltransferase 3 alpha) located on Chromosome 2. What is the predicted biological effect — harmless or disease-causing? | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | CCTTGCCTCCCCATCAGAGCAGTTTCCATTCCTCACTCAGCCCTCTCGTGGATTGCAAAGGCTCTTCCAGACAGAGGAGGCCTCCTTCATTGTGCTTCCCCCGAGCTAACCACACAGATTTCCTTACCACGATCCCTCCCCCTCCAGAAATGCTAGCCGAACTGAGGCAAGGAAACAATCAGAGCAGATCCCGAGAGGGTCTCGGGAGAAACAGGGTACGGCACTGTTTCTGCTGCTCCCAACATGTCCCCCAGCCAAGGAGCTTTTACAGCCTCCTGGGGTGTGACATGATTTAAGAAGGCCTCAAGGTTCCAGTCTGG... | CCTTGCCTCCCCATCAGAGCAGTTTCCATTCCTCACTCAGCCCTCTCGTGGATTGCAAAGGCTCTTCCAGACAGAGGAGGCCTCCTTCATTGTGCTTCCCCCGAGCTAACCACACAGATTTCCTTACCACGATCCCTCCCCCTCCAGAAATGCTAGCCGAACTGAGGCAAGGAAACAATCAGAGCAGATCCCGAGAGGGTCTCGGGAGAAACAGGGTACGGCACTGTTTCTGCTGCTCCCAACATGTCCCCCAGCCAAGGAGCTTTTACAGCCTCCTGGGGTGTGACATGATTTAAGAAGGCCTCAAGGTTCCAGTCTGG... |
Task1_train_3166 | Mutation context: Chromosome 2, Gene DNMT3A (DNA methyltransferase 3 alpha). Determine if this variant is likely to be benign or pathogenic. Mention the disease if applicable. | Pathogenic; not provided | CCCATCAGAGCAGTTTCCATTCCTCACTCAGCCCTCTCGTGGATTGCAAAGGCTCTTCCAGACAGAGGAGGCCTCCTTCATTGTGCTTCCCCCGAGCTAACCACACAGATTTCCTTACCACGATCCCTCCCCCTCCAGAAATGCTAGCCGAACTGAGGCAAGGAAACAATCAGAGCAGATCCCGAGAGGGTCTCGGGAGAAACAGGGTACGGCACTGTTTCTGCTGCTCCCAACATGTCCCCCAGCCAAGGAGCTTTTACAGCCTCCTGGGGTGTGACATGATTTAAGAAGGCCTCAAGGTTCCAGTCTGGGATACAAAA... | CCCATCAGAGCAGTTTCCATTCCTCACTCAGCCCTCTCGTGGATTGCAAAGGCTCTTCCAGACAGAGGAGGCCTCCTTCATTGTGCTTCCCCCGAGCTAACCACACAGATTTCCTTACCACGATCCCTCCCCCTCCAGAAATGCTAGCCGAACTGAGGCAAGGAAACAATCAGAGCAGATCCCGAGAGGGTCTCGGGAGAAACAGGGTACGGCACTGTTTCTGCTGCTCCCAACATGTCCCCCAGCCAAGGAGCTTTTACAGCCTCCTGGGGTGTGACATGATTTAAGAAGGCCTCAAGGTTCCAGTCTGGGATACAAAA... |
Task1_train_3167 | Here is a variant affecting DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Please identify whether it is a benign mutation or associated with a disorder. | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | TCTGGGATACAAAAAGCTGTAAATGAACTTCTCTAGGTTTACAGAAGAGCAGCATGGAGCTGAGAACAGAAGACAAACATCTGGCCGGGGAAGCCATCCCCTCCGCCTCACCCTCTAACCAGGGTCCCTGGGTTGAGACTGCCTATCTCCCTCTGGCCAAAGACATGAATTCTAAGAAGAGCTATTCCTTTCTTAAAAGCCGGGAAGCCCTTGGCTGGGGGGGCAGGGCAGAGGGGTGGATGTGTCTTCACAATCTCCTAGGACGCTTTCTGCAGTGTCCAGAGTCACATGAAGCAAACAATGCCTGCAGGGTGACCCAG... | TCTGGGATACAAAAAGCTGTAAATGAACTTCTCTAGGTTTACAGAAGAGCAGCATGGAGCTGAGAACAGAAGACAAACATCTGGCCGGGGAAGCCATCCCCTCCGCCTCACCCTCTAACCAGGGTCCCTGGGTTGAGACTGCCTATCTCCCTCTGGCCAAAGACATGAATTCTAAGAAGAGCTATTCCTTTCTTAAAAGCCGGGAAGCCCTTGGCTGGGGGGGCAGGGCAGAGGGGTGGATGTGTCTTCACAATCTCCTAGGACGCTTTCTGCAGTGTCCAGAGTCACATGAAGCAAACAATGCCTGCAGGGTGACCCAG... |
Task1_train_3168 | Here is a genetic alteration in DNMT3A (DNA methyltransferase 3 alpha) on Chromosome 2. Based on the data, is it a benign variant or a cause of disease? | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | CTGGGCAACAGACTCCGTCTCAAAAAAAAAAAAAAAAATGTAGCTTTATATCGCTTGACATGAAAAAGCAATCATAATATAATAAATGCAAGGCAAGTTACAAAACCGTGTGCATTCACTACCCACTTAATTTATCTATCTATGGATGTATGGTTATATAAACACAAACGCACAGAAAAAAATCTGAAAAGGACATATGCCAAAATATTAATAAAAGGATAATGGGTGATTTAAATAAGTCTTCTTTAGACTATCTTGTGTATAATCAAAACACAACAGAACTGTGTATGTTTCTGTCTTGCTGAATCTGTCCTTTGAGG... | CTGGGCAACAGACTCCGTCTCAAAAAAAAAAAAAAAAATGTAGCTTTATATCGCTTGACATGAAAAAGCAATCATAATATAATAAATGCAAGGCAAGTTACAAAACCGTGTGCATTCACTACCCACTTAATTTATCTATCTATGGATGTATGGTTATATAAACACAAACGCACAGAAAAAAATCTGAAAAGGACATATGCCAAAATATTAATAAAAGGATAATGGGTGATTTAAATAAGTCTTCTTTAGACTATCTTGTGTATAATCAAAACACAACAGAACTGTGTATGTTTCTGTCTTGCTGAATCTGTCCTTTGAGG... |
Task1_train_3169 | A variant was discovered in gene DNMT3A (DNA methyltransferase 3 alpha), Chromosome 2. Please indicate if this mutation results in a known disease or if it's non-harmful. | Pathogenic; Heyn-Sproul-Jackson syndrome | CCTGCTCATGAGAAGCAGCCCTGGTTCCAGGTTACTCAGGAGGGATTCCCGGGGTAATCCTCAAGTCCTGACCCCTGCCCCAATCCTCCCAGGCCGAGGGTCCTGAGCCAGATCCACCAGCACCAGGCTGAGGGCGACAGCCCCAGGATGAGAGAGGTGAGCAAAGGTGAAAGGCTGAAAGGGGACCTGTAGGTGAGTTCAGTCACACCCAAGAGGGGCTGCCCTTCTGTGGCCACTGGGGAGTCCCACACCCTGAAGACCAGCCCACGCCATTGACAGGAGAGCAGAATCATGGCACCAGAAAGACAGACAGTGCACGA... | CCTGCTCATGAGAAGCAGCCCTGGTTCCAGGTTACTCAGGAGGGATTCCCGGGGTAATCCTCAAGTCCTGACCCCTGCCCCAATCCTCCCAGGCCGAGGGTCCTGAGCCAGATCCACCAGCACCAGGCTGAGGGCGACAGCCCCAGGATGAGAGAGGTGAGCAAAGGTGAAAGGCTGAAAGGGGACCTGTAGGTGAGTTCAGTCACACCCAAGAGGGGCTGCCCTTCTGTGGCCACTGGGGAGTCCCACACCCTGAAGACCAGCCCACGCCATTGACAGGAGAGCAGAATCATGGCACCAGAAAGACAGACAGTGCACGA... |
Task1_train_3170 | With a mutation on Chromosome 2 in gene DNMT3A (DNA methyltransferase 3 alpha), classify this variant as benign or pathogenic. Include the disease if it's pathogenic. | Pathogenic; Tatton-Brown-Rahman overgrowth syndrome | CTCAAGTCCTGACCCCTGCCCCAATCCTCCCAGGCCGAGGGTCCTGAGCCAGATCCACCAGCACCAGGCTGAGGGCGACAGCCCCAGGATGAGAGAGGTGAGCAAAGGTGAAAGGCTGAAAGGGGACCTGTAGGTGAGTTCAGTCACACCCAAGAGGGGCTGCCCTTCTGTGGCCACTGGGGAGTCCCACACCCTGAAGACCAGCCCACGCCATTGACAGGAGAGCAGAATCATGGCACCAGAAAGACAGACAGTGCACGAAGCACGGTGAAGGTGGTGTGACACGCAGGACGTGGCCCCTGGTCCCATGTCATTCAAAC... | CTCAAGTCCTGACCCCTGCCCCAATCCTCCCAGGCCGAGGGTCCTGAGCCAGATCCACCAGCACCAGGCTGAGGGCGACAGCCCCAGGATGAGAGAGGTGAGCAAAGGTGAAAGGCTGAAAGGGGACCTGTAGGTGAGTTCAGTCACACCCAAGAGGGGCTGCCCTTCTGTGGCCACTGGGGAGTCCCACACCCTGAAGACCAGCCCACGCCATTGACAGGAGAGCAGAATCATGGCACCAGAAAGACAGACAGTGCACGAAGCACGGTGAAGGTGGTGTGACACGCAGGACGTGGCCCCTGGTCCCATGTCATTCAAAC... |
Task1_train_3171 | This genomic variant is located on Chromosome 2, within the DNMT3A (DNA methyltransferase 3 alpha) gene. Can you determine its pathogenicity and name any linked disease? | Pathogenic; Inborn genetic diseases | AGGGTCCTGAGCCAGATCCACCAGCACCAGGCTGAGGGCGACAGCCCCAGGATGAGAGAGGTGAGCAAAGGTGAAAGGCTGAAAGGGGACCTGTAGGTGAGTTCAGTCACACCCAAGAGGGGCTGCCCTTCTGTGGCCACTGGGGAGTCCCACACCCTGAAGACCAGCCCACGCCATTGACAGGAGAGCAGAATCATGGCACCAGAAAGACAGACAGTGCACGAAGCACGGTGAAGGTGGTGTGACACGCAGGACGTGGCCCCTGGTCCCATGTCATTCAAACCTTCCTAAGTGCCTCTGCTACTCTGCCCCATGCCACA... | AGGGTCCTGAGCCAGATCCACCAGCACCAGGCTGAGGGCGACAGCCCCAGGATGAGAGAGGTGAGCAAAGGTGAAAGGCTGAAAGGGGACCTGTAGGTGAGTTCAGTCACACCCAAGAGGGGCTGCCCTTCTGTGGCCACTGGGGAGTCCCACACCCTGAAGACCAGCCCACGCCATTGACAGGAGAGCAGAATCATGGCACCAGAAAGACAGACAGTGCACGAAGCACGGTGAAGGTGGTGTGACACGCAGGACGTGGCCCCTGGTCCCATGTCATTCAAACCTTCCTAAGTGCCTCTGCTACTCTGCCCCATGCCACA... |
Task1_train_3172 | Located on Chromosome 2, this mutation impacts GAREM2, HADHA (GRB2 associated regulator of MAPK1 subtype 2| hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha). What is its biological consequence — is it benign or pathogenic, and which disease is associated if any? | Pathogenic; not specified | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... |
Task1_train_3173 | A variant was discovered on Chromosome 2, affecting GAREM2, HADHA (GRB2 associated regulator of MAPK1 subtype 2| hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha). What is its functional impact — neutral or pathogenic? State the disease if pathogenic. | Pathogenic; Mitochondrial trifunctional protein deficiency | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... |
Task1_train_3174 | Mutation context: Chromosome 2, Gene GAREM2, HADHA (GRB2 associated regulator of MAPK1 subtype 2| hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha). Determine if this variant is likely to be benign or pathogenic. Mention the disease if applicable. | Pathogenic; Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... |
Task1_train_3175 | The gene GAREM2, HADHA (GRB2 associated regulator of MAPK1 subtype 2| hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha) on Chromosome 2 contains a mutation. Based on this information, is the variant pathogenic or benign? Provide the disease if relevant. | Pathogenic; Mitochondrial trifunctional protein deficiency | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... |
Task1_train_3176 | Consider this mutation in GAREM2, HADHA (GRB2 associated regulator of MAPK1 subtype 2| hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha) on Chromosome 2. Is this a benign change or a disease-causing variant? | Pathogenic; Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... |
Task1_train_3177 | The following genetic variant occurs in GAREM2, HADHA (GRB2 associated regulator of MAPK1 subtype 2| hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha) on Chromosome 2. Classify its clinical effect — pathogenic or benign — and list any associated condition. | Pathogenic; HADHA-related disorder | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... |
Task1_train_3178 | A mutation on Chromosome 2 affecting GAREM2, HADHA (GRB2 associated regulator of MAPK1 subtype 2| hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha) has been found. Is it harmful or harmless? What disease, if any, does it cause? | Pathogenic; Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... |
Task1_train_3179 | Assess the clinical impact of this variant on gene GAREM2, HADHA (GRB2 associated regulator of MAPK1 subtype 2| hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha), found on Chromosome 2. State whether it’s pathogenic or benign, and the disease if applicable. | Pathogenic; Mitochondrial trifunctional protein deficiency 1 | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... |
Task1_train_3180 | A genetic alteration is present in GAREM2, HADHA (GRB2 associated regulator of MAPK1 subtype 2| hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha) on Chromosome 2. Is this variant benign or disease-causing, and if the latter, which condition is involved? | Pathogenic; Inborn genetic diseases | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... | CTTGCTTCTGCACTATTGCAGATTTCATCTCTGGGGGATAAAAATGCTTGTCCATCTGGCATAACTTGGACCAGGTGATGCTAGAGCCCCAGAAGGGTAGAACTCTGCCTTTTGTCCATAATCTATAGTCCTAGCCCTTAGAAGGTTCACATGACATCTTTTTTTTTTTTTTTTTTTGAGAAGGGGCCTCGCCATGTTGCCCAGGCTGGCCTCACACTTCTGGGCTCAAGCGATCCTCCCACCTCAGCCTCCTAAGCAGCTAAGACCATAAGTGGTTGCTACCGCACCTGACTCATAAAATCATTTTTGAAATCGCCAGT... |
Task1_train_3181 | This is a variant in HADHA (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha), located on Chromosome 2. Is this mutation a likely cause of disease or not? | Pathogenic; Mitochondrial trifunctional protein deficiency | GCTCTTCACTTATTAGAACTGATGGAATGCGTTATTCATATGAAAGATTAATTTGTAAAGAGACAATAGATAAGGAATTCCAGTTATCATCCAAGGCAAGGGGGAAGGGGCCTAGAGAAATAATAGTGGAAGAATTACTGATAACTGGGAAAGCAGGAAGGGGGACACCCTATCTACAATGTTCATTATTCAATTTTCAGTTTAACATATTTTGCCTTGGGTATCTTATAGCTTATTCTTCATTTCTAAGATGATGCTAACTTTTTCTTCAATGTCTTTCCCAAGTTAGGTCAACTCCTATATTTATCCTGTTTTTCTGC... | GCTCTTCACTTATTAGAACTGATGGAATGCGTTATTCATATGAAAGATTAATTTGTAAAGAGACAATAGATAAGGAATTCCAGTTATCATCCAAGGCAAGGGGGAAGGGGCCTAGAGAAATAATAGTGGAAGAATTACTGATAACTGGGAAAGCAGGAAGGGGGACACCCTATCTACAATGTTCATTATTCAATTTTCAGTTTAACATATTTTGCCTTGGGTATCTTATAGCTTATTCTTCATTTCTAAGATGATGCTAACTTTTTCTTCAATGTCTTTCCCAAGTTAGGTCAACTCCTATATTTATCCTGTTTTTCTGC... |
Task1_train_3182 | This is a variant in HADHA (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha), located on Chromosome 2. Is this mutation a likely cause of disease or not? | Pathogenic; not specified | CTAGGCTTTGGATATTTTTTTCCTTTTTCAGCTTTATACAGAGGATTGGATCTTTAGTTTTCCTTTAACTGATAATAAAACATTGAAAGGAAATAAGTTTACCTGAGATTCACAGAGATAACCGGCATCACTCCCTTGCTCAATTCCAGTCTTTACCACCTAAAAAACATATAAAGCACTTGCTCAGCGTTGGAATAGATTGGCGAGATGTACAATAATGCTGAATAAAATTGCCAGTGTTGTTAGTCCTCAAAGAGTAAGTCAAAAGTCTAGACTGGAATGAGAAAGAGAAGAGGACTGAGGATCTGGCTGCTCTCGAC... | CTAGGCTTTGGATATTTTTTTCCTTTTTCAGCTTTATACAGAGGATTGGATCTTTAGTTTTCCTTTAACTGATAATAAAACATTGAAAGGAAATAAGTTTACCTGAGATTCACAGAGATAACCGGCATCACTCCCTTGCTCAATTCCAGTCTTTACCACCTAAAAAACATATAAAGCACTTGCTCAGCGTTGGAATAGATTGGCGAGATGTACAATAATGCTGAATAAAATTGCCAGTGTTGTTAGTCCTCAAAGAGTAAGTCAAAAGTCTAGACTGGAATGAGAAAGAGAAGAGGACTGAGGATCTGGCTGCTCTCGAC... |
Task1_train_3183 | This gene mutation involves HADHB (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta) on Chromosome 2. Is it associated with any clinical condition, or is it benign? | Pathogenic; Mitochondrial trifunctional protein deficiency | CATACCATTACTTGTAACATACTTTTTGGTTTATACATTCTGTGATATGGAGAGGGAGGCAGCTAGACAAGGATGTGAATACCAAGAGGTAGAGATTATTGGGGGGCAACTTGGAGGCTGGCTACCAAAGTCTTTGTTGGTAAATCTTGTGGGATTTTTTTGGTTTTGATTTTTTGTTGTTGTTGTTAAAACATGCTTCAAAATTAAGAAATTATAAAAGGTGTGTGATGACAAGTCTTCCACCCCTGACCCCTAGTTACCCAGTTCCCTTTCTTCCAGCCAACAATTATTTTTAACATCTTTATTATACTTCCAGGGGG... | CATACCATTACTTGTAACATACTTTTTGGTTTATACATTCTGTGATATGGAGAGGGAGGCAGCTAGACAAGGATGTGAATACCAAGAGGTAGAGATTATTGGGGGGCAACTTGGAGGCTGGCTACCAAAGTCTTTGTTGGTAAATCTTGTGGGATTTTTTTGGTTTTGATTTTTTGTTGTTGTTGTTAAAACATGCTTCAAAATTAAGAAATTATAAAAGGTGTGTGATGACAAGTCTTCCACCCCTGACCCCTAGTTACCCAGTTCCCTTTCTTCCAGCCAACAATTATTTTTAACATCTTTATTATACTTCCAGGGGG... |
Task1_train_3184 | Assess the clinical impact of this variant on gene HADHB (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta), found on Chromosome 2. State whether it’s pathogenic or benign, and the disease if applicable. | Pathogenic; Mitochondrial trifunctional protein deficiency 2 | TTTTTTTTTTTTAACACAGAACCTCACTCTGTCACTCAGGCTGGAGTGCAGTGGTACCATCATAGCTCACTGCAGGCTCAAACTCTTGAGCTCAAGAGATCATCCTGCCTTAGGATCCCAAGTAGCTGGGTCTACAGGTGCTCCACCACACCCAGCTAATTTTTAAATTTTTTGTGGAGACGGGATCTCGCCATGTTGCCCAGGCTGGTCTTAAACCTCTGGCCTCAAGTGATCCTTCTACCTCAGCCTCCAAAGTGCTGGGATTACAGGCGTGAGCCACCATGCTCATCCCAAAAAGTACTCTTAACAGAAGTAAAAGA... | TTTTTTTTTTTTAACACAGAACCTCACTCTGTCACTCAGGCTGGAGTGCAGTGGTACCATCATAGCTCACTGCAGGCTCAAACTCTTGAGCTCAAGAGATCATCCTGCCTTAGGATCCCAAGTAGCTGGGTCTACAGGTGCTCCACCACACCCAGCTAATTTTTAAATTTTTTGTGGAGACGGGATCTCGCCATGTTGCCCAGGCTGGTCTTAAACCTCTGGCCTCAAGTGATCCTTCTACCTCAGCCTCCAAAGTGCTGGGATTACAGGCGTGAGCCACCATGCTCATCCCAAAAAGTACTCTTAACAGAAGTAAAAGA... |
Task1_train_3185 | Chromosome 2 houses a mutation in gene HADHB (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta). Classify its clinical impact — is it pathogenic or benign, and what disease does it lead to if any? | Pathogenic; Mitochondrial trifunctional protein deficiency | TGGTGCATCTGCAATGTTAATCATGGCGGAGGAAAAGGCTCTGGCCATGGGTTATAAGCCGAAGGCATATTTGAGGTAAAGTAAATGTTCAAACAAATCATCTCTGATTTCTTTATTTTATTACCAAAGCTCACCTCTCTATTTTTTTACCTAGGGATTTTATGTATGTGTCTCAGGATCCAAAAGATCAACTATTACTTGGGTAGGTAGCAGTTTGTATCCTTGGACTATAATCACAAGTATTTGATTGCCTATGTTTTATTATACTGGTTAATAAATGATTAACACTGGTTTATTATTTATTTGTTTATTACACTGGT... | TGGTGCATCTGCAATGTTAATCATGGCGGAGGAAAAGGCTCTGGCCATGGGTTATAAGCCGAAGGCATATTTGAGGTAAAGTAAATGTTCAAACAAATCATCTCTGATTTCTTTATTTTATTACCAAAGCTCACCTCTCTATTTTTTTACCTAGGGATTTTATGTATGTGTCTCAGGATCCAAAAGATCAACTATTACTTGGGTAGGTAGCAGTTTGTATCCTTGGACTATAATCACAAGTATTTGATTGCCTATGTTTTATTATACTGGTTAATAAATGATTAACACTGGTTTATTATTTATTTGTTTATTACACTGGT... |
Task1_train_3186 | A variant affecting Chromosome 2, within the gene HADHB (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta), has been observed. Determine if it's benign or associated with disease. | Pathogenic; Mitochondrial trifunctional protein deficiency 1 | TGGTGCATCTGCAATGTTAATCATGGCGGAGGAAAAGGCTCTGGCCATGGGTTATAAGCCGAAGGCATATTTGAGGTAAAGTAAATGTTCAAACAAATCATCTCTGATTTCTTTATTTTATTACCAAAGCTCACCTCTCTATTTTTTTACCTAGGGATTTTATGTATGTGTCTCAGGATCCAAAAGATCAACTATTACTTGGGTAGGTAGCAGTTTGTATCCTTGGACTATAATCACAAGTATTTGATTGCCTATGTTTTATTATACTGGTTAATAAATGATTAACACTGGTTTATTATTTATTTGTTTATTACACTGGT... | TGGTGCATCTGCAATGTTAATCATGGCGGAGGAAAAGGCTCTGGCCATGGGTTATAAGCCGAAGGCATATTTGAGGTAAAGTAAATGTTCAAACAAATCATCTCTGATTTCTTTATTTTATTACCAAAGCTCACCTCTCTATTTTTTTACCTAGGGATTTTATGTATGTGTCTCAGGATCCAAAAGATCAACTATTACTTGGGTAGGTAGCAGTTTGTATCCTTGGACTATAATCACAAGTATTTGATTGCCTATGTTTTATTATACTGGTTAATAAATGATTAACACTGGTTTATTATTTATTTGTTTATTACACTGGT... |
Task1_train_3187 | This gene mutation involves HADHB (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta) on Chromosome 2. Is it associated with any clinical condition, or is it benign? | Pathogenic; Mitochondrial trifunctional protein deficiency | GCAATGTTAATCATGGCGGAGGAAAAGGCTCTGGCCATGGGTTATAAGCCGAAGGCATATTTGAGGTAAAGTAAATGTTCAAACAAATCATCTCTGATTTCTTTATTTTATTACCAAAGCTCACCTCTCTATTTTTTTACCTAGGGATTTTATGTATGTGTCTCAGGATCCAAAAGATCAACTATTACTTGGGTAGGTAGCAGTTTGTATCCTTGGACTATAATCACAAGTATTTGATTGCCTATGTTTTATTATACTGGTTAATAAATGATTAACACTGGTTTATTATTTATTTGTTTATTACACTGGTTTGAGAGTAT... | GCAATGTTAATCATGGCGGAGGAAAAGGCTCTGGCCATGGGTTATAAGCCGAAGGCATATTTGAGGTAAAGTAAATGTTCAAACAAATCATCTCTGATTTCTTTATTTTATTACCAAAGCTCACCTCTCTATTTTTTTACCTAGGGATTTTATGTATGTGTCTCAGGATCCAAAAGATCAACTATTACTTGGGTAGGTAGCAGTTTGTATCCTTGGACTATAATCACAAGTATTTGATTGCCTATGTTTTATTATACTGGTTAATAAATGATTAACACTGGTTTATTATTTATTTGTTTATTACACTGGTTTGAGAGTAT... |
Task1_train_3188 | A variant affecting Chromosome 2, within the gene HADHB (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta), has been observed. Determine if it's benign or associated with disease. | Pathogenic; Mitochondrial trifunctional protein deficiency 2 | AGTGAGCCAAGATCACGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCATCTCAAAAAAATAAATAAATAAATAAAATAGTAGTAATCCTTTCCATTGGTATATCATGTTACAGTTTTGGATTATTTTCCATTTTTTTCCTATAAGTTTTACATATATATATGGACACACACAACTTATATTCTTTTTCATTAAGATAGCATATGCATTTTTTCATATGGCTACACACCCTGCTACACAATCTTCCTAATATAGCCTTTTATAAAAGCCTCCCCATGTTTAGACTCTGTTCCGTTCCCTCACAAGGCTGTAGCC... | AGTGAGCCAAGATCACGCCACTGCACTCCAGCCTGGGCGACAGAGCGAGACTCCATCTCAAAAAAATAAATAAATAAATAAAATAGTAGTAATCCTTTCCATTGGTATATCATGTTACAGTTTTGGATTATTTTCCATTTTTTTCCTATAAGTTTTACATATATATATGGACACACACAACTTATATTCTTTTTCATTAAGATAGCATATGCATTTTTTCATATGGCTACACACCCTGCTACACAATCTTCCTAATATAGCCTTTTATAAAAGCCTCCCCATGTTTAGACTCTGTTCCGTTCCCTCACAAGGCTGTAGCC... |
Task1_train_3189 | Gene HADHB (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta) on Chromosome 2 is altered by this variant. Does this mutation result in a disease or is it benign? | Pathogenic; Mitochondrial trifunctional protein deficiency 2 | TGGGCGACAGAGCGAGACTCCATCTCAAAAAAATAAATAAATAAATAAAATAGTAGTAATCCTTTCCATTGGTATATCATGTTACAGTTTTGGATTATTTTCCATTTTTTTCCTATAAGTTTTACATATATATATGGACACACACAACTTATATTCTTTTTCATTAAGATAGCATATGCATTTTTTCATATGGCTACACACCCTGCTACACAATCTTCCTAATATAGCCTTTTATAAAAGCCTCCCCATGTTTAGACTCTGTTCCGTTCCCTCACAAGGCTGTAGCCTCTAGCCTCCACTGTGACGTTCACATCAGTCAA... | TGGGCGACAGAGCGAGACTCCATCTCAAAAAAATAAATAAATAAATAAAATAGTAGTAATCCTTTCCATTGGTATATCATGTTACAGTTTTGGATTATTTTCCATTTTTTTCCTATAAGTTTTACATATATATATGGACACACACAACTTATATTCTTTTTCATTAAGATAGCATATGCATTTTTTCATATGGCTACACACCCTGCTACACAATCTTCCTAATATAGCCTTTTATAAAAGCCTCCCCATGTTTAGACTCTGTTCCGTTCCCTCACAAGGCTGTAGCCTCTAGCCTCCACTGTGACGTTCACATCAGTCAA... |
Task1_train_3190 | Assess the clinical impact of this variant on gene HADHB (hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta), found on Chromosome 2. State whether it’s pathogenic or benign, and the disease if applicable. | Pathogenic; Mitochondrial trifunctional protein deficiency | TGGGCGACAGAGCGAGACTCCATCTCAAAAAAATAAATAAATAAATAAAATAGTAGTAATCCTTTCCATTGGTATATCATGTTACAGTTTTGGATTATTTTCCATTTTTTTCCTATAAGTTTTACATATATATATGGACACACACAACTTATATTCTTTTTCATTAAGATAGCATATGCATTTTTTCATATGGCTACACACCCTGCTACACAATCTTCCTAATATAGCCTTTTATAAAAGCCTCCCCATGTTTAGACTCTGTTCCGTTCCCTCACAAGGCTGTAGCCTCTAGCCTCCACTGTGACGTTCACATCAGTCAA... | TGGGCGACAGAGCGAGACTCCATCTCAAAAAAATAAATAAATAAATAAAATAGTAGTAATCCTTTCCATTGGTATATCATGTTACAGTTTTGGATTATTTTCCATTTTTTTCCTATAAGTTTTACATATATATATGGACACACACAACTTATATTCTTTTTCATTAAGATAGCATATGCATTTTTTCATATGGCTACACACCCTGCTACACAATCTTCCTAATATAGCCTTTTATAAAAGCCTCCCCATGTTTAGACTCTGTTCCGTTCCCTCACAAGGCTGTAGCCTCTAGCCTCCACTGTGACGTTCACATCAGTCAA... |
Task1_train_3191 | This sequence change occurs on Chromosome 2, altering SELENOI (selenoprotein I). What is the medical significance of this variant — is it benign or linked to a disease? | Pathogenic; Spastic paraplegia 81, autosomal recessive | GGCGGGGCAGAGGCGCTCCCCACATCCCAGACGATGGGCAGCCGGGCAGAGACGCTCCTCACTTCCTAGATGTGATGGCGGCCGGGAAGAGGCGCTCCTCACTTCCCAGATGGGGTGGCGGCCGGGCAGAGGCTGCAATCTTGGCACTTTGGGAGGCCAAGGCAGGCGGCTGGGAGGTGGAGGTTGTAGCGAGCCGAGATCACGCCACTGCACTCCAGCCTGGGCGCCATTGAGCACTGAGTGAACCAGACTCCGTCTGCAATCCCGGCACCTCGGGAGGCCGAGGCTGGCGGATCACTCGCGGTTAGGAGCTGGAGACC... | GGCGGGGCAGAGGCGCTCCCCACATCCCAGACGATGGGCAGCCGGGCAGAGACGCTCCTCACTTCCTAGATGTGATGGCGGCCGGGAAGAGGCGCTCCTCACTTCCCAGATGGGGTGGCGGCCGGGCAGAGGCTGCAATCTTGGCACTTTGGGAGGCCAAGGCAGGCGGCTGGGAGGTGGAGGTTGTAGCGAGCCGAGATCACGCCACTGCACTCCAGCCTGGGCGCCATTGAGCACTGAGTGAACCAGACTCCGTCTGCAATCCCGGCACCTCGGGAGGCCGAGGCTGGCGGATCACTCGCGGTTAGGAGCTGGAGACC... |
Task1_train_3192 | The variant affects gene OTOF (otoferlin), which is on Chromosome 2. Please evaluate whether this mutation is benign or pathogenic and specify the disease if necessary. | Pathogenic; Auditory neuropathy, autosomal recessive, 1 | AAGTGGGATGTTGTAGTGAACCTTGGCCTCATAATGACCCTTGGCCTGTGACAGGACCCAGACATTCTGGACGGTATGGTTCCCGCTTCCACAGATGCTACTGTATACAAGAGGCTGGGGGAGGAAGAGGTGGGGCAGGCTAGATTGGGGATGGCATGGGTGCGTGGAGAGAGGAGAGGGGAAGACTGCAGAGAATGGACGGGCGGGAGATGAAGAACGCTACCAGAGGTCACAGCTGGAGCAGAAGCTGAGCAAGAAGGCTCAGGCGTGTCTCCTGCAGGGAGGCAGTCTGTGGGTGTTCAGCATCTCTCAGCTTTGGA... | AAGTGGGATGTTGTAGTGAACCTTGGCCTCATAATGACCCTTGGCCTGTGACAGGACCCAGACATTCTGGACGGTATGGTTCCCGCTTCCACAGATGCTACTGTATACAAGAGGCTGGGGGAGGAAGAGGTGGGGCAGGCTAGATTGGGGATGGCATGGGTGCGTGGAGAGAGGAGAGGGGAAGACTGCAGAGAATGGACGGGCGGGAGATGAAGAACGCTACCAGAGGTCACAGCTGGAGCAGAAGCTGAGCAAGAAGGCTCAGGCGTGTCTCCTGCAGGGAGGCAGTCTGTGGGTGTTCAGCATCTCTCAGCTTTGGA... |
Task1_train_3193 | This genomic variant is located on Chromosome 2, within the OTOF (otoferlin) gene. Can you determine its pathogenicity and name any linked disease? | Pathogenic; Autosomal recessive nonsyndromic hearing loss 9 | TTGGGGATGGCATGGGTGCGTGGAGAGAGGAGAGGGGAAGACTGCAGAGAATGGACGGGCGGGAGATGAAGAACGCTACCAGAGGTCACAGCTGGAGCAGAAGCTGAGCAAGAAGGCTCAGGCGTGTCTCCTGCAGGGAGGCAGTCTGTGGGTGTTCAGCATCTCTCAGCTTTGGAGAGGAGATGCGTGCAGGGCTTTGGAGGCCCATGGGAGAGCCAGCGTGGCTCGCAAGGGTGGCAAAGAAGGAGGGCCCTGGGAAAAATGTAACGACTTTCACCCTTTCTTTTCCAGATCAACTCTGAACTGCAAGTTCCTCCCAC... | TTGGGGATGGCATGGGTGCGTGGAGAGAGGAGAGGGGAAGACTGCAGAGAATGGACGGGCGGGAGATGAAGAACGCTACCAGAGGTCACAGCTGGAGCAGAAGCTGAGCAAGAAGGCTCAGGCGTGTCTCCTGCAGGGAGGCAGTCTGTGGGTGTTCAGCATCTCTCAGCTTTGGAGAGGAGATGCGTGCAGGGCTTTGGAGGCCCATGGGAGAGCCAGCGTGGCTCGCAAGGGTGGCAAAGAAGGAGGGCCCTGGGAAAAATGTAACGACTTTCACCCTTTCTTTTCCAGATCAACTCTGAACTGCAAGTTCCTCCCAC... |
Task1_train_3194 | A genetic alteration is present in OTOF (otoferlin) on Chromosome 2. Is this variant benign or disease-causing, and if the latter, which condition is involved? | Pathogenic; OTOF-related disorder | TTGGGGATGGCATGGGTGCGTGGAGAGAGGAGAGGGGAAGACTGCAGAGAATGGACGGGCGGGAGATGAAGAACGCTACCAGAGGTCACAGCTGGAGCAGAAGCTGAGCAAGAAGGCTCAGGCGTGTCTCCTGCAGGGAGGCAGTCTGTGGGTGTTCAGCATCTCTCAGCTTTGGAGAGGAGATGCGTGCAGGGCTTTGGAGGCCCATGGGAGAGCCAGCGTGGCTCGCAAGGGTGGCAAAGAAGGAGGGCCCTGGGAAAAATGTAACGACTTTCACCCTTTCTTTTCCAGATCAACTCTGAACTGCAAGTTCCTCCCAC... | TTGGGGATGGCATGGGTGCGTGGAGAGAGGAGAGGGGAAGACTGCAGAGAATGGACGGGCGGGAGATGAAGAACGCTACCAGAGGTCACAGCTGGAGCAGAAGCTGAGCAAGAAGGCTCAGGCGTGTCTCCTGCAGGGAGGCAGTCTGTGGGTGTTCAGCATCTCTCAGCTTTGGAGAGGAGATGCGTGCAGGGCTTTGGAGGCCCATGGGAGAGCCAGCGTGGCTCGCAAGGGTGGCAAAGAAGGAGGGCCCTGGGAAAAATGTAACGACTTTCACCCTTTCTTTTCCAGATCAACTCTGAACTGCAAGTTCCTCCCAC... |
Task1_train_3195 | Gene OTOF (otoferlin) on Chromosome 2 is altered by this variant. Does this mutation result in a disease or is it benign? | Pathogenic; Inborn genetic diseases | TTGGGGATGGCATGGGTGCGTGGAGAGAGGAGAGGGGAAGACTGCAGAGAATGGACGGGCGGGAGATGAAGAACGCTACCAGAGGTCACAGCTGGAGCAGAAGCTGAGCAAGAAGGCTCAGGCGTGTCTCCTGCAGGGAGGCAGTCTGTGGGTGTTCAGCATCTCTCAGCTTTGGAGAGGAGATGCGTGCAGGGCTTTGGAGGCCCATGGGAGAGCCAGCGTGGCTCGCAAGGGTGGCAAAGAAGGAGGGCCCTGGGAAAAATGTAACGACTTTCACCCTTTCTTTTCCAGATCAACTCTGAACTGCAAGTTCCTCCCAC... | TTGGGGATGGCATGGGTGCGTGGAGAGAGGAGAGGGGAAGACTGCAGAGAATGGACGGGCGGGAGATGAAGAACGCTACCAGAGGTCACAGCTGGAGCAGAAGCTGAGCAAGAAGGCTCAGGCGTGTCTCCTGCAGGGAGGCAGTCTGTGGGTGTTCAGCATCTCTCAGCTTTGGAGAGGAGATGCGTGCAGGGCTTTGGAGGCCCATGGGAGAGCCAGCGTGGCTCGCAAGGGTGGCAAAGAAGGAGGGCCCTGGGAAAAATGTAACGACTTTCACCCTTTCTTTTCCAGATCAACTCTGAACTGCAAGTTCCTCCCAC... |
Task1_train_3196 | This gene mutation involves OTOF (otoferlin) on Chromosome 2. Is it associated with any clinical condition, or is it benign? | Pathogenic; Autosomal recessive nonsyndromic hearing loss 9 | GTGCAGATGAGGTACTTGATGGACTTGAGAGGGTTGAGGAACCAGACGAAGGCCGTGTCGGGCCGGCTGGGAAGTGGAAGAGAGGAGCCGGTCAGCCAGTGGGCAGGAGCTGCCTCCCAGTGCACCCCATCCTCTGTCCTTCTGGACCCCCAAAAGCCCTGCCATGGCCCCAGCCCCAAAAGCAGTGAATGCTGGAGCCAGGGTTTAAACCCATTTCTAAGTACCCGACTTGCTGCTTACAAAACTCTATCCTCCCTGCAGCACCTTTGGGGCCCGAATCTCCTCCTAAGGCCTAGATGGGAGCTACTTGCAGCATGGGG... | GTGCAGATGAGGTACTTGATGGACTTGAGAGGGTTGAGGAACCAGACGAAGGCCGTGTCGGGCCGGCTGGGAAGTGGAAGAGAGGAGCCGGTCAGCCAGTGGGCAGGAGCTGCCTCCCAGTGCACCCCATCCTCTGTCCTTCTGGACCCCCAAAAGCCCTGCCATGGCCCCAGCCCCAAAAGCAGTGAATGCTGGAGCCAGGGTTTAAACCCATTTCTAAGTACCCGACTTGCTGCTTACAAAACTCTATCCTCCCTGCAGCACCTTTGGGGCCCGAATCTCCTCCTAAGGCCTAGATGGGAGCTACTTGCAGCATGGGG... |
Task1_train_3197 | This mutation is located in gene OTOF (otoferlin) on Chromosome 2. Is it associated with a disease or is it a benign polymorphism? | Pathogenic; Autosomal recessive nonsyndromic hearing loss 9 | CTTCACCTCTTTGGCTTAATGTGGAAAAGTGTAAAATAGTCATTTCTAGTTCTGAGAGTCTATTCTGTCATGAAAGCTTGAAAGTTGCTGTGCATGTTTGTGTGGGCTTAAGTGTGTGCCTGTGTGTGCTTGAGTGCATGTGTATGCACTTGTGCGTGGCACATGTGTGCATACATGCTTGTGTGTGTTTGTGTGCACATGTATGCATATTTGTGTTTGTGGATGTGTGCGTGTATATGTGTGTGTGTGCACGCGCCTGCCTAGCCCTTGGTCCAGAGGAAGAAGTAAGAAATATCAGACCCAGGAGGCCACTGGGCTCA... | CTTCACCTCTTTGGCTTAATGTGGAAAAGTGTAAAATAGTCATTTCTAGTTCTGAGAGTCTATTCTGTCATGAAAGCTTGAAAGTTGCTGTGCATGTTTGTGTGGGCTTAAGTGTGTGCCTGTGTGTGCTTGAGTGCATGTGTATGCACTTGTGCGTGGCACATGTGTGCATACATGCTTGTGTGTGTTTGTGTGCACATGTATGCATATTTGTGTTTGTGGATGTGTGCGTGTATATGTGTGTGTGTGCACGCGCCTGCCTAGCCCTTGGTCCAGAGGAAGAAGTAAGAAATATCAGACCCAGGAGGCCACTGGGCTCA... |
Task1_train_3198 | Here is a genetic alteration in OTOF (otoferlin) on Chromosome 2. Based on the data, is it a benign variant or a cause of disease? | Pathogenic; Bilateral sensorineural hearing impairment | GCCCCACCCAGCTCAGTCCCTCCCATGCAGGGACTGCTCACCCACCCCCTCACGAAGATGTCACTGGACTTCTCCCCTGTGAAGAAGTCGTCGTCCTCCAAGACCACCTCATCTGTGTTCCAGATGATGACCCGCAGCTCGTACCTGGGCCCAGGGAGAGAAGGCTGGTTAGCAGCCCCAGGTGGGGGTTATGCCAGGGTGCCAGGGCTGGGATGGGGCAGGCGGAGAGAAGCCCTGGGGTCTTGGGGTCAGCACAGGGCCTGGGCCAGGCTGGGGCTGGAGGAGTGGTTTGGGGTTGGGGGAGCAGAGGCATGAGTGAG... | GCCCCACCCAGCTCAGTCCCTCCCATGCAGGGACTGCTCACCCACCCCCTCACGAAGATGTCACTGGACTTCTCCCCTGTGAAGAAGTCGTCGTCCTCCAAGACCACCTCATCTGTGTTCCAGATGATGACCCGCAGCTCGTACCTGGGCCCAGGGAGAGAAGGCTGGTTAGCAGCCCCAGGTGGGGGTTATGCCAGGGTGCCAGGGCTGGGATGGGGCAGGCGGAGAGAAGCCCTGGGGTCTTGGGGTCAGCACAGGGCCTGGGCCAGGCTGGGGCTGGAGGAGTGGTTTGGGGTTGGGGGAGCAGAGGCATGAGTGAG... |
Task1_train_3199 | A sequence alteration has been identified in OTOF (otoferlin) on Chromosome 2. Is it disease-inducing or harmless? | Pathogenic; Autosomal recessive nonsyndromic hearing loss 9 | GCTGGACTTGAACCTGCCGCTTTATGGATGGGAAACCCGGGTTCTTTTCACTCTACCACCTCCTGCCTCTTCCAGGCACTCACTCCTGGATTCATCACTGGCAGGCACTCCAAAGAAAACTTGGCGGAACATCACACTAGCCTGGATGTGAGGATGACGCAGGGCCGGCTCCCAGGGGTTCTGTGTGTTGTGAAGGAGTGCGTCAGTGTGGGCATGTGTGTGGGTGTCCGTGGGAGTGCTATGCTGTGTGTGTGTGTGTGCATGAGATGCATGTGTATGGGCGCGTAGACCGTGTAGATACAATGCACCGGAGTGTGCTG... | GCTGGACTTGAACCTGCCGCTTTATGGATGGGAAACCCGGGTTCTTTTCACTCTACCACCTCCTGCCTCTTCCAGGCACTCACTCCTGGATTCATCACTGGCAGGCACTCCAAAGAAAACTTGGCGGAACATCACACTAGCCTGGATGTGAGGATGACGCAGGGCCGGCTCCCAGGGGTTCTGTGTGTTGTGAAGGAGTGCGTCAGTGTGGGCATGTGTGTGGGTGTCCGTGGGAGTGCTATGCTGTGTGTGTGTGTGTGCATGAGATGCATGTGTATGGGCGCGTAGACCGTGTAGATACAATGCACCGGAGTGTGCTG... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.